@article {pmid41407606,
year = {2025},
author = {Ouksel, H},
title = {[Long covid pulmonary rehabilitation].},
journal = {Revue des maladies respiratoires},
volume = {},
number = {},
pages = {},
doi = {10.1016/j.rmr.2025.12.001},
pmid = {41407606},
issn = {1776-2588},
abstract = {While the SARS-CoV-2 pandemic has left a lasting impression, the long-term effects of this virus, such as persistent symptoms or long COVID, remain unclear. However, recommendations from learned societies for improving these symptoms exist and are being applied by a number of respiratory rehabilitation centers. In this paper, we provide a summary of the specificities of long COVID care in the context of respiratory rehabilitation, particularly as regards respiratory symptoms, fatigue, cognitive disorders, and cardiovascular symptoms and, more specifically, vegetative dysautonomia. The key elements of support are Therapeutic Patient Education (TPE) and activity management and fractionated exercise (PACING). While the effects of respiratory rehabilitation are highly promising, with potential improvement in symptoms and exercise capacity, the level of evidence remains low to moderate. Structured and coordinated multidisciplinary work is of paramount importance as a means of providing for these individuals the best possible support on their road to recovery. Further studies are needed to improve the level of evidence on the effectiveness of rehabilitation in cases of long COVID.},
}

@article {pmid41407484,
year = {2025},
author = {Wilson, JC and Liu, KY and Mittelman, E and Bareke, P and Shleifer, E and Howard, R},
title = {Brain fog with long covid and chemotherapy: systematic review and meta-analysis.},
journal = {BMJ mental health},
volume = {28},
number = {1},
pages = {},
doi = {10.1136/bmjment-2025-301969},
pmid = {41407484},
issn = {2755-9734},
mesh = {Humans ; *COVID-19/complications/psychology ; *Antineoplastic Agents/adverse effects ; *Neoplasms/drug therapy ; SARS-CoV-2 ; *Cognitive Dysfunction/etiology ; },
abstract = {QUESTION: What are the cognitive, functional and affective characteristics of brain fog in individuals with long covid and following chemotherapy, and how are these features assessed across studies?

STUDY SELECTION AND ANALYSIS: In March 2024, we conducted a systematic review and meta-analysis of peer-reviewed studies assessing cognition, function or mood in adults (≥18 years) with brain fog after COVID-19 or chemotherapy. PubMed, Embase and Web of Science were searched systematically according to eligibility criteria to March 2024, with an update in May 2025. Random-effects meta-analyses using the 'dmetar' package (V.0.0.9000) in R V.4.3.1 were performed for studies comparing individuals with and without brain fog. Bias was assessed using the National Institutes of Health Study Quality Assessment Tools.

FINDINGS: Of 3077 records screened, 65 studies met inclusion criteria: 40 investigated brain fog in long covid and 25 in chemotherapy populations. Considerable variation in assessment tools was observed. Montreal Cognitive Assessment was the most common cognitive test in long covid studies; Functional Assessment of Cancer Therapy-Cognitive Function was most used in chemotherapy studies. Nine long covid studies were eligible for meta-analysis. Compared with controls, individuals with brain fog had significantly lower cognitive performance (Hedge's g=-0.63, 95% CI -1.15 to -0.12), higher fatigue (Hedge's g=2.64, 95% CI 0.41 to 4.86) and more depressive symptoms (Hedge's g=1.48, 95% CI 0.40 to 2.55). Heterogeneity was high (I[2]>70%). No chemotherapy studies were appropriate for meta-analysis, preventing direct comparison of brain fog features between long covid and chemotherapy groups.

CONCLUSIONS: Brain fog in long covid and chemotherapy populations is associated with cognitive complaints, fatigue and mood disturbance, though assessment methods differ widely. To improve comparability and clinical understanding, we propose adoption of consistent tools and definitions in future studies. This will be a crucial step in generating findings that can be meaningfully compared across populations.

PROSPERO REGISTRATION NUMBER: CRD42024520549.},
}

Humans
*COVID-19/complications/psychology
*Antineoplastic Agents/adverse effects
*Neoplasms/drug therapy
SARS-CoV-2
*Cognitive Dysfunction/etiology

@article {pmid41406849,
year = {2025},
author = {Asokan, S and Choudekar, A and Jagadeesan, A and Sm, R and Ali, A and Napte, SU and Selvam, SA and Verma, G and Das, P and Beniwal, N and Radhamanalan, G and Vijayan, S and Rajeswary, D and Jacob, T},
title = {Molecular diagnostics in clinical microbiology: Advances, applications, and future directions.},
journal = {Diagnostic microbiology and infectious disease},
volume = {114},
number = {3},
pages = {117223},
doi = {10.1016/j.diagmicrobio.2025.117223},
pmid = {41406849},
issn = {1879-0070},
abstract = {Molecular diagnostics have transformed clinical microbiology by enabling rapid, accurate, and highly sensitive detection of infectious agents, significantly improving patient outcomes and public health response. Over the past decade, advances in polymerase chain reaction (PCR), next-generation sequencing (NGS), digital PCR, isothermal amplification, and CRISPR-based assays have enhanced pathogen identification, antimicrobial resistance profiling, and outbreak investigation. These technologies have been instrumental in detecting and monitoring emerging and re-emerging viral pathogens such as SARS-CoV-2, Nipah, Zika, H5N1 avian influenza, Mpox, Ebola, Marburg, and MERS-CoV. Molecular diagnostics also play a critical role in antimicrobial resistance surveillance and hospital infection control by enabling high-resolution tracking of resistance genes and pathogen transmission dynamics. Despite these achievements, challenges remain regarding implementation costs, technical expertise, infrastructure, and the need for global standardization. Future directions focus on developing cost-effective, point-of-care molecular platforms, integrating artificial intelligence and bioinformatics for enhanced interpretation, and applying these technologies within One Health and environmental surveillance frameworks. These innovations will be pivotal for early outbreak detection, real-time data-driven decision-making, and equitable access to advanced diagnostics worldwide. Ultimately, molecular diagnostics are poised to remain the cornerstone of precision medicine and infectious disease control in the era of global health challenges.},
}

@article {pmid41406676,
year = {2025},
author = {Ward, J and Gressani, O and Kim, S and Hens, N and Edmunds, WJ},
title = {The epidemiology of pathogens with pandemic potential: A review of key parameters and clustering analysis.},
journal = {Epidemics},
volume = {54},
number = {},
pages = {100882},
doi = {10.1016/j.epidem.2025.100882},
pmid = {41406676},
issn = {1878-0067},
abstract = {INTRODUCTION: In the light of the COVID-19 pandemic many countries are trying to widen their pandemic planning from its traditional focus on influenza. However, it is impossible to draw up detailed plans for every pathogen with epidemic potential. We set out to try to simplify this process by reviewing the epidemiology of a range of pathogens with pandemic potential and seeing whether they fall into groups with shared epidemiological traits.

METHODS: We reviewed the epidemiological characteristics of 19 different pathogens with pandemic potential (those on the WHO priority list of pathogens, different strains of influenza and Mpox). We extracted data on key parameters (reproduction number serial interval, proportion of presymptomatic transmission, case fatality risk and transmission route) and applied an unsupervised learning algorithm. This combined Monte Carlo sampling with ensemble clustering to classify pathogens into distinct epidemiological archetypes based on their shared characteristics.

RESULTS: From 154 articles we extracted 302 epidemiological parameter estimates. The clustering algorithms categorise these pathogens into six archetypes (1) highly transmissible Coronaviruses, (2) moderately transmissible Coronaviruses, (3) high-severity contact and zoonotic pathogens, (4) Influenza viruses (5) MERS-CoV-like and (6) MPV-like.

CONCLUSION: Unsupervised learning on epidemiological data can be used to define distinct pathogen archetypes. This method offers a valuable framework to allocate emerging and novel pathogens into defined groups to evaluate common approaches for their control.},
}

@article {pmid41405828,
year = {2025},
author = {Constantin, M and Barbu, I and Vrancianu, CO and Chifiriuc, MC and Pitică, IM and Casangiu, A and Ruță, SM and Bleotu, C},
title = {Retroviral Remnants in the Human Genome: Classification, Integration and Regulation.},
journal = {Molecular diagnosis & therapy},
volume = {},
number = {},
pages = {},
pmid = {41405828},
issn = {1179-2000},
support = {CNFIS-FDI-2025-F-0364//UB Research Nexus: Transforming Research through Innovation, Digitalization and Exploration at the University of Bucharest/ ; Component C9/Investment no. 8 (I8) - contract CF 68//Ministry of Research, Innovation and Digitalization through the National Recovery and Resilience Plan (PNRR) of Romania, Pillar III/ ; PNRR-III-C9-2023 (I8)- CF 53 - 760231/28.12.2023//Design and Implementation of Base-Relief DNA Origami: A multilevel approach to DNA Nanotechnology/ ; project no. 23020101//The core program within the National Research Development and Innovation Plan, 2022-2027', carried out with the support of the Ministry of Research, Innovation and Digitalization (MCID/ ; Contract no. 7N from 3 January 2023//The core program within the National Research Development and Innovation Plan, 2022-2027', carried out with the support of the Ministry of Research, Innovation and Digitalization (MCID/ ; },
abstract = {Human endogenous retroviruses (HERVs) are remnants of ancient retroviral infections constituting nearly 8% of the human genome. Far from being inert genetic fossils, HERVs have co-evolved with their hosts, acquiring regulatory and functional roles that influence development, immunity and disease. In this comprehensive review, we examine the origin, evolutionary dynamics and structural diversity of HERVs, emphasising their integration, genomic organisation and mosaic recombination patterns. We further highlight how epigenetic modifications, intracellular factors such as transcriptional regulators, hormones and cytokines, and environmental influences regulate HERV expression. By synthesising current evidence linking HERV activity to immune modulation, tumourigenesis, autoimmunity and neurodegenerative processes, we provide an integrated perspective on their dual role as drivers of pathology and contributors to normal physiology. Our analysis underscores that HERVs are not only markers of past infections but also active genomic elements with potential clinical implications, from biomarker discovery to novel therapeutic targets, making their systematic investigation timely and highly relevant.},
}

@article {pmid41405805,
year = {2025},
author = {Blair, HA},
title = {Sublingual Cyclobenzaprine: First Approval.},
journal = {Clinical drug investigation},
volume = {},
number = {},
pages = {},
pmid = {41405805},
issn = {1179-1918},
abstract = {TONMYA[™] is a sublingual eutectic formulation of cyclobenzaprine being developed by Tonix Pharmaceuticals for the treatment of various conditions, including fibromyalgia, post-traumatic stress disorder (PTSD), acute stress disorder, major depressive disorder, post-acute COVID-19 syndrome, alcohol use disorder, and agitation in Alzheimer's disease. The sublingual formulation was designed for rapid transmucosal absorption to produce diurnal variation in peak-to-trough drug concentrations, making it suitable for long-term bedtime use. On 15 August 2025, sublingual cyclobenzaprine was approved for the treatment of fibromyalgia in adults in the USA. This article summarizes the milestones in the development of sublingual cyclobenzaprine leading to this first approval for fibromyalgia.},
}

@article {pmid41405643,
year = {2025},
author = {Nawrooz, MS and Taher, WM and Alwan, M and Jawad, M and Mushtaq, H and Allela, OQB},
title = {The role of low-density lipoprotein receptors in emerging and reemerging viruses: a review with examples from human metapneumovirus and beyond.},
journal = {Archives of microbiology},
volume = {208},
number = {1},
pages = {79},
pmid = {41405643},
issn = {1432-072X},
mesh = {Humans ; *Receptors, LDL/metabolism ; *Metapneumovirus/physiology ; *Communicable Diseases, Emerging/virology ; *Paramyxoviridae Infections/virology/metabolism ; Animals ; Virus Replication ; Virus Internalization ; SARS-CoV-2 ; Antiviral Agents/pharmacology ; },
abstract = {The frequency of new and re-emerging viral infections is rising, driven by shifts in environmental conditions and altered interactions between hosts, vectors, and pathogens. New treatments may be developed through a better understanding of the molecular processes underlying viral replication. The low-density lipoprotein receptor (LDLR) serves as a critical entry portal for a diverse range of infectious agents, facilitating the initiation and perpetuation of their infection cycles. Furthermore, numerous viruses, such as the dengue virus and the hepatitis C virus (HCV), depend on host cholesterol (CHO) for replication and spread. Consequently, targeting the LDLR with pharmacological agents presents a promising therapeutic strategy for a broad spectrum of viral infections, including those caused by human immunodeficiency virus (HIV), HCV, and severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). In addition, human metapneumovirus (HMPV) is a leading cause of respiratory infections in young children, underscoring the need for effective treatments. This research investigates the role of the LDLR in HMPV and other emerging viruses. A key finding is that HMPV infection depends on LDLR-mediated pathways, as evidenced by the rapid recovery observed after exogenous CHO administration. Therefore, understanding the mechanism of LDLR in viral entry and replication is crucial and presents a promising avenue for developing novel antiviral therapies.},
}

Humans
*Receptors, LDL/metabolism
*Metapneumovirus/physiology
*Communicable Diseases, Emerging/virology
*Paramyxoviridae Infections/virology/metabolism
Animals
Virus Replication
Virus Internalization
SARS-CoV-2
Antiviral Agents/pharmacology

@article {pmid41405551,
year = {2025},
author = {Wang, L and Lin, C and Chuai, Y and Zhang, Q and Qin, S and Luo, Z and Li, Y},
title = {Home-used coronavirus sensors powered by isothermal amplification.},
journal = {Journal of materials chemistry. B},
volume = {},
number = {},
pages = {},
doi = {10.1039/d5tb01673h},
pmid = {41405551},
issn = {2050-7518},
abstract = {The global pandemic caused by coronaviruses, particularly SARS-CoV-2, has highlighted the urgent need for biosensing platforms that enable early and self-administered viral detection. Home-used biosensors enable rapid, accurate, and highly sensitive detection in home settings, reducing the probability of cross-infection while circumventing the temporal, financial, and operational constraints of conventional hospital-based workflows. However, they face limitations in sensitivity. Isothermal nucleic acid amplification strategies under constant or ambient temperature conditions present a transformative solution, leveraging mild reaction conditions and operational simplicity to advance household-compatible diagnostics. In recent years, a variety of innovative at-home sensors with advanced performance have been developed based on different isothermal amplification strategies, including loop-mediated isothermal amplification, clustered regularly interspaced short palindromic repeats, hybridization chain reaction, catalytic hairpin assembly, entropy-driven circuit and so on. Mainly taking the novel coronavirus as an example, this review systematically summarized the latest progress in the construction and application of household coronavirus sensors from three aspects: the targets of detection, the signal amplification strategies, and the biosensing platforms (fluorescence, Raman spectroscopy, surface plasmon resonance, colorimetry, and electrochemistry), as well as emphasized their advantages and challenges. We further delineate persistent challenges and future trajectories for enhancing the accessibility, accuracy, and multiplexing capacity of decentralized diagnostic platforms.},
}

@article {pmid41405493,
year = {2025},
author = {McTavish, C and McGillis Hall, L and Price, S and Visekruna, S and Blain, A},
title = {Worsening Shortages, Mass Departures, Intolerable Working Conditions: A Media Analysis of Canada's Nursing Workforce Crisis.},
journal = {International nursing review},
volume = {72},
number = {4},
pages = {e70140},
doi = {10.1111/inr.70140},
pmid = {41405493},
issn = {1466-7657},
support = {WI2 179956/CAPMC/CIHR/Canada ; },
mesh = {Humans ; *COVID-19/epidemiology/nursing ; Canada/epidemiology ; *Mass Media/statistics & numerical data ; Pandemics ; Health Policy ; *Nursing Staff/supply & distribution ; SARS-CoV-2 ; Working Conditions ; },
abstract = {AIM: To explore the nature and content of Canadian media coverage surrounding the COVID-19 pandemic by wave - spanning from 2020 to 2024, identifying health policy and system responses that emerged as strategies in retaining the nursing workforce.

BACKGROUND: COVID-19 was an unprecedented health crisis impacting healthcare delivery and the healthcare workforce globally. It caused tremendous turbulence and strain, testing system capacity due to staff shortages, resource limitations and issues accommodating high volumes and acuity levels of patients. Across Canada, the pandemic resulted in mobilization of policy and system responses to address workforce challenges that emerged.

METHODS: A qualitative content analysis was conducted of online media coverage from nursing organizations and government websites published from January 2020 to March 2024, as well as newspaper articles from the Canadian Newsstream database.

RESULTS: Synthesized findings were categorized according to waves of the pandemic, highlighting key themes surrounding system and policy responses that emerged. Government investments to increase wages, educate additional staff and enhance protection for workers were among the measures employed.

DISCUSSION: This review captures the evolution and progression of the health crisis, its impact on the nursing workforce and associated responses. Workforce development and retention were emphasized through measures to enhance mental health and wellness, improve protection for workers and address safe staffing practices.

CONCLUSION: Nurses played a pivotal role throughout the global pandemic. Multiple system and policy responses were identified as key facets in strengthening, supporting and sustaining the nursing workforce.

Measures implemented illustrate the instrumental role that stakeholders, including the government and nursing organizations, play in building capacity and prioritizing efforts to protect nurses and enhance preparedness for future outbreaks.},
}

Humans
*COVID-19/epidemiology/nursing
Canada/epidemiology
*Mass Media/statistics & numerical data
Pandemics
Health Policy
*Nursing Staff/supply & distribution
SARS-CoV-2
Working Conditions

@article {pmid41404505,
year = {2025},
author = {Islam, MS and Monir, SB and Haque, N and Vabna, MA and Fan, J and Li, Y and Nime, I and Feroz, F and Acharjee, M and Pan, F},
title = {Immunometabolic crossroads: infections as bidirectional modulators in diabetes and metabolic syndromes.},
journal = {Frontiers in endocrinology},
volume = {16},
number = {},
pages = {1710157},
pmid = {41404505},
issn = {1664-2392},
mesh = {Humans ; *Metabolic Syndrome/immunology/metabolism ; *Diabetes Mellitus/immunology/metabolism ; Animals ; COVID-19/immunology ; *Infections/immunology/metabolism/complications ; Inflammation/immunology/metabolism ; Insulin Resistance ; },
abstract = {Diabetes and metabolic disorders represent a global health crisis driven by complex interactions between metabolic, immune, and microbial networks. Beyond their metabolic derangements- hyperglycemia, insulin resistance, and low-grade systemic inflammation-these disorders are now recognized to exist at an immunometabolic interface profoundly influenced by infectious agent The bidirectional relationship between infections and metabolic dysregulation highlighting how acute and chronic infections contribute to insulin resistance, β-cell dysfunction, and systemic inflammation, while metabolic dysregulation impairs immune competence, predisposing individuals to recurrent and severe infections. Pathogens such as Helicobacter pylori Staphylococcus aureus, Escherichia coli, SARS-CoV-2, and hepatitis viruses, alter host metabolic signaling through inflammatory, mitochondrial, and hormonal pathways, reshaping glucose and lipid homeostasis. In turn, diabetic immune impairment amplifies susceptibility to pneumonia, urinary tract infections, and chronic wound infections, reinforcing a pathogenic feedback loop. Emerging therapeutic strategies including nanotechnology enabled, therapeutics, gene, and stem cell based interventions and next-generation incretin agonists- including tirzepatide and CagriSem offer promising avenues to restore both metabolic balance and immune resilience. Additionally, foundational strategies such as lifestyle modifications, medical nutrition therapy, and vaccination remain essential components of disease control. Understanding infections as dynamic modulators of metabolic homeostasis reframes diabetes not merely as an endocrine disorder, but as a systemic immunometabolic disease. This review synthesizes current evidence on infection induced metabolic syndrome, immune impairments, and innovative therapeutic strategies to guide future precision interventions at the infection-metabolism interface.},
}

Humans
*Metabolic Syndrome/immunology/metabolism
*Diabetes Mellitus/immunology/metabolism
Animals
COVID-19/immunology
*Infections/immunology/metabolism/complications
Inflammation/immunology/metabolism
Insulin Resistance

@article {pmid41404126,
year = {2025},
author = {Serradell, L and Fretta, A and Nachbar, J and Dreyfus, J and Garofalo, D and Lucini, A and Mather, S and Esposito, D and Chabanon, AL and Bauchau, V and Sellers, S},
title = {The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective.},
journal = {Frontiers in drug safety and regulation},
volume = {5},
number = {},
pages = {1650992},
pmid = {41404126},
issn = {2674-0869},
abstract = {During the pandemic, the accelerated review and authorization of coronavirus disease 19 (COVID-19) vaccines by regulatory authorities elicited the need for rapid and thorough worldwide signal detection and evaluation. To meet this need, the European Medicines Agency and other health authorities expected that, in addition to routine signal detection, COVID-19 vaccine manufacturers should leverage observed-to-expected (O/E) analyses unconventionally as a quantitative method for signal detection of adverse events of special interest (AESIs). The objective of O/E analyses in vaccine signal detection was to determine if AESIs were occurring at a higher-than-expected rate in the vaccinated population in comparison with an unexposed population. The use of O/E was intended to mitigate the challenge of analyzing large volumes of individual case safety reports (ICSRs) received over a very short period following mass vaccination campaigns. The "Beyond COVID-19 Monitoring Excellence" (BeCOME) initiative, a non-competitive voluntary initiative launched in 2022 by COVID-19 vaccine Marketing Authorization Holders (MAHs) and key stakeholders, was established to align systems, enhance processes, and foster innovation in post-marketing vaccine monitoring, building on lessons from the pandemic. A dedicated working group was created to review and share MAHs' experience on O/E analyses used as an additional tool for signal detection during the COVID-19 pandemic. This review presents the industry perspective on using O/E analyses for COVID-19 vaccine signal detection, including challenges and limitations encountered, and proposes best practices for future improvement. Despite the priority and resources devoted to O/E analyses, no de novo signals resulting in the identification of safety concerns were detected using this methodology during the COVID-19 pandemic. O/E analyses are most useful when source data are accurate and there is a high level of confidence in the assumptions and parameters used. In the context of the COVID-19 pandemic, confidence in certain assumptions and parameters was low, limiting the value of O/E analyses in signal detection. Nevertheless, O/E analyses applied for signal refinement, as traditionally used, proved to be useful. Industry experiences support maintaining O/E analyses as a tool for signal refinement and standardizing methodological approaches as much as possible to enhance its future application and comparability across stakeholders.},
}

@article {pmid41403919,
year = {2026},
author = {Regmi, A and Sami, A and Baral, S and Niraula, BB and Jain, VK and Iyengar, KP},
title = {Temporal onset and steroid-associated risk in post-COVID hip avascular necrosis: A systematic review and pooled analysis.},
journal = {Journal of orthopaedics},
volume = {72},
number = {},
pages = {304-311},
pmid = {41403919},
issn = {0972-978X},
abstract = {BACKGROUND: Avascular necrosis (AVN) of the hip has emerged as a post-COVID musculoskeletal complication, likely driven by corticosteroid therapy and virus-induced microvascular injury. This study systematically reviews published evidence on post-COVID AVN, analyzing pooled data on latency, cumulative steroid dose, staging, and management outcomes.

METHODS: A systematic review and pooled analysis were conducted following PRISMA guidelines. PubMed, Embase and Scopus, were searched up to June 2024 using predefined keywords. Studies reporting AVN of the hip following confirmed COVID-19 infection were included. Quantitative pooling of latency (days from infection to AVN diagnosis) and cumulative steroid dose (mg prednisolone equivalent) was performed using a random-effects model.

RESULTS: Seventeen studies encompassing 209 patients (313 hips) were included. The mean age was 43.7 ± 16.2 years, with a male predominance. Pooled analysis showed a mean latency of 126.48 days (95 % CI: 95.5-157.46) from COVID-19 infection to AVN onset and a mean cumulative steroid dose of 1198.44 mg (95 % CI: 860.99-1535.88). Most cases presented at Ficat-Arlet stages II-III. Core decompression and bisphosphonate therapy were effective in early stages, while total hip arthroplasty was required for advanced disease.

CONCLUSION: Post-COVID AVN of the hip is a delayed yet potentially preventable sequela associated with corticosteroid exposure and COVID-related vascular injury. The mean latency of 126 days from infection to AVN onset and an average cumulative corticosteroid exposure of 1198 mg prednisolone equivalent underscores the delayed yet dose-dependent nature of this condition.},
}

@article {pmid41403560,
year = {2025},
author = {Dandachi, I and Aljabr, W},
title = {MERS-COV in the Middle East, a one health concept approach.},
journal = {One health (Amsterdam, Netherlands)},
volume = {21},
number = {},
pages = {101282},
pmid = {41403560},
issn = {2352-7714},
abstract = {The MERS-COV virus is a zoonotic coronavirus that emerged in 2012 in KSA and caused viral illness with a case fatality rate up to 35 %. Over a decade later, the virus is still evolving and circulating. The aim of this review is to discuss the current epidemiology of MERS-COV both in humans and animals, during and post the COVID-19 pandemic. We have found that MERS-COV is still evolving in camels with new lineages being detected in Saudi Arabia. Although the number of human cases has decreased, there is a gradual resurgence in the number of cases. Furthermore, many cases are being reported without exposure to camels and/or raw products, nor contact with known human cases. This necessitates global efforts in the surveillance of asymptomatic carriers in the community, role of unknown animal reservoirs in the virus spread if any, as well as extensive genomic surveillance of the virus. This is in order to unveil and assess the genetic changes that the virus is undergoing and their according effect on the viral fitness, tropism, and virulence. These efforts are crucial for potential future pandemic preparedness, understanding the modes of transmission, as well as drug and vaccine development for MERS-COV.},
}

@article {pmid41402837,
year = {2025},
author = {Syam, N and Abbas, MZ},
title = {From proposal to compromise: the TRIPS waiver debate and the crisis of WTO decision-making.},
journal = {Globalization and health},
volume = {},
number = {},
pages = {},
doi = {10.1186/s12992-025-01176-7},
pmid = {41402837},
issn = {1744-8603},
abstract = {The Marrakesh Agreement, which established the World Trade Organization (WTO), permits WTO member countries to jointly decide to temporarily suspend certain obligations under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement). The TRIPS Decision adopted at the 12th WTO Ministerial Conference in June 2022, following 20 months of extended negotiations during the COVID-19 pandemic, approved only a limited portion of the waiver proposal originally submitted by India and South Africa. Since the Decision was adopted, WTO members have faced a deadlock over whether to extend its scope to include COVID-19 diagnostics and therapeutics, despite being required by the Decision to reach a conclusion on this issue within six months. This paper re-examines the discussions surrounding the potential expansion of the Decision and argues that including COVID-19 diagnostics and therapeutics within its scope was both appropriate and necessary. In addition, the paper proposes ways to make effective use of TRIPS flexibilities during a pandemic, so that developing countries are not left dependent on unpredictable waiver negotiations. The paper also outlines possible approaches for reforming the waiver decision-making process, aiming to ensure that such decisions are made promptly and efficiently, without prolonged negotiations during times of emergency.Clinical trial number Not applicable.},
}

@article {pmid41401799,
year = {2025},
author = {Monteiro, H and Oliveira, M and Martinho, R and Martins, C},
title = {Managing Data in Screening Programs: Challenges and Solutions.},
journal = {Acta medica portuguesa},
volume = {},
number = {},
pages = {},
doi = {10.20344/amp.23363},
pmid = {41401799},
issn = {1646-0758},
abstract = {Population-based screening programs are vital public health initiatives that enable the early detection of diseases, significantly reducing both morbidity and healthcare costs. As these programs expand, the management of the extensive data they generate becomes increasingly complex, highlighting the need for structured digital solutions. This narrative review article presents a pragmatic framework aimed at clarifying big data analytics tailored to the needs and practices of healthcare professionals and administrators, focusing on effective integration into routine screening workflows. To achieve effective data utilization, the process begins with systematic archiving, which involves cloud-based storage solutions capable of securely maintaining various data formats in compliance with regulatory standards, thus ensuring long-term accessibility and continuity. Subsequent real-time processing of screening data facilitates rapid decision-making and patient management by providing immediate validation and analysis, essential for maintaining the responsiveness of screening services. Transformation processes play a critical role in converting diverse data inputs into standardized, consistent formats, enabling seamless communication and exchange among multiple healthcare systems. Integration further builds upon this standardization, merging data from different healthcare providers and diagnostic centers into centralized analytical platforms. This unified approach enables comprehensive patient monitoring and supports predictive modeling for early identification of at-risk individuals. Advanced analytics, particularly process mining and predictive techniques, reveal inefficiencies within screening workflows, highlighting areas needing improvement. These methods help healthcare managers to streamline operations, optimize resources, and enhance overall program performance. Real-time visualization tools provide administrators with continuous, practical insights into operational dynamics, despite existing challenges related to data governance and system interoperability. This article illustrates these concepts through concrete examples from the colorectal cancer screening program in Northern Portugal and the response to the COVID-19 pandemic. The colorectal cancer screening scenario demonstrates how structured data management significantly boosts operational efficiency and healthcare accessibility. Meanwhile, the COVID-19 experience highlights the importance of having flexible digital infrastructures capable of quickly adapting to unexpected crises. Finally, ongoing investments in digital infrastructure, professional training, and comprehensive data governance are crucial for sustaining these improvements. This review provides clear, actionable knowledge to support healthcare professionals in adopting big data analytics effectively within preventive healthcare programs.},
}

@article {pmid41395986,
year = {2026},
author = {He, Z and Liu, M and Xie, Q and Lu, H and Guo, C},
title = {Autophagy and ubiquitination in important swine viral infections: Host defense and viral antagonism.},
journal = {Virulence},
volume = {17},
number = {1},
pages = {2605370},
doi = {10.1080/21505594.2025.2605370},
pmid = {41395986},
issn = {2150-5608},
mesh = {Animals ; *Autophagy ; Swine ; *Ubiquitination ; Porcine epidemic diarrhea virus/immunology ; *Host-Pathogen Interactions ; *Swine Diseases/virology/immunology ; African Swine Fever Virus/immunology ; Porcine respiratory and reproductive syndrome virus/immunology ; Virus Diseases/veterinary ; Immune Evasion ; },
abstract = {Swine viral infections continue to impose major economic and animal-health burdens worldwide, with pathogens such as porcine epidemic diarrhea virus (PEDV), African swine fever virus (ASFV), and porcine reproductive and respiratory syndrome virus (PRRSV) causing recurrent outbreaks. Autophagy and ubiquitination are central degradative pathways that act as double-edged swords, serving both host defense and viral exploitation. In this narrative review, we synthesize recent advances showing how these pathogens manipulate ubiquitin - autophagy circuits while host cells counteract through selective autophagy. We propose an autophagy - metabolism - immunity triad that positions autophagy as a hub linking infection, metabolic reprogramming, and immune evasion. This integrated framework moves beyond the traditional view of autophagy as strictly antiviral or pro-viral. Deciphering how viruses hijack ubiquitin - autophagy axes reveals actionable therapeutic targets and translational opportunities for antivirals, adjuvants, and metabolic interventions to reduce the burden of swine viral diseases.},
}

Animals
*Autophagy
Swine
*Ubiquitination
Porcine epidemic diarrhea virus/immunology
*Host-Pathogen Interactions
*Swine Diseases/virology/immunology
African Swine Fever Virus/immunology
Porcine respiratory and reproductive syndrome virus/immunology
Virus Diseases/veterinary
Immune Evasion

@article {pmid41117600,
year = {2025},
author = {Batac, ALR and Marks, M and Tucker, JD and Peeling, RŴ},
title = {Syphilis self-testing and implications for syphilis control and prevention.},
journal = {Journal of clinical microbiology},
volume = {63},
number = {12},
pages = {e0098225},
doi = {10.1128/jcm.00982-25},
pmid = {41117600},
issn = {1098-660X},
mesh = {Humans ; *Syphilis/diagnosis/prevention & control/epidemiology ; *Self-Testing ; COVID-19 ; *Syphilis Serodiagnosis/methods ; },
abstract = {The incidence of syphilis has risen dramatically in many regions despite the availability of affordable facility-based testing and curative treatment. The recent approval of over-the-counter syphilis self-tests (SSTs) represents an important advance for expanding diagnostic access and disease control and prevention. Evidence demonstrates that SSTs are accurate, usable, and acceptable. However, as with HIV and COVID-19 self-testing, implementation challenges remain, including ensuring equitable access, supporting vulnerable groups, securing linkage to care, and maintaining quality assurance.},
}

Humans
*Syphilis/diagnosis/prevention & control/epidemiology
*Self-Testing
COVID-19
*Syphilis Serodiagnosis/methods

@article {pmid40536568,
year = {2025},
author = {Li, L and Zhao, C and Hou, S},
title = {Efficacy and safety of imatinib in patients with COVID-19: a systematic review and meta-analysis.},
journal = {Wiener klinische Wochenschrift},
volume = {137},
number = {23-24},
pages = {778-786},
pmid = {40536568},
issn = {1613-7671},
mesh = {Humans ; *Imatinib Mesylate/therapeutic use/adverse effects ; *COVID-19 Drug Treatment ; COVID-19/mortality ; Treatment Outcome ; Randomized Controlled Trials as Topic ; SARS-CoV-2 ; },
abstract = {OBJECTIVE: To inform treatment decisions in clinical practice, we conducted a meta-analysis to evaluate the efficacy and safety of imatinib in patients with COVID-19.

METHODS: A comprehensive systematic search was conducted across multiple electronic databases to identify relevant randomized controlled trials (RCTs) comparing imatinib with placebo in patients with COVID-19. A meta-analysis was performed using Review Manager software version 5.3 and followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

RESULTS: The analysis included 4 studies with a total of 717 patients. The risk ratio (RR) for 28-day mortality in the imatinib group compared to the placebo group was 0.79 (95% confidence interval. CI 0.51-1.21; p = 0.28). There were no statistically significant differences in the duration of oxygen supplementation (MD = -0.13, 95% CI -2.57-2.31; p = 0.92) or the number of ventilator-free days (MD = 4.71, 95% CI -6.97-16.38; p = 0.43). Imatinib treatment did not significantly reduce the duration of hospital or intensive care unit (ICU) stay. Additionally, there was no significant difference between imatinib and placebo in the risk of any adverse events (AEs) or serious AEs.

CONCLUSION: Imatinib did not significantly improve clinical outcomes in patients with COVID-19. Future research should consider subgroup analyses based on the biological heterogeneity of COVID-19-associated acute respiratory distress syndrome (ARDS) or the concurrent use of interleukin 6 (IL-6) receptor inhibitors to identify patient populations that may benefit from imatinib treatment.},
}

Humans
*Imatinib Mesylate/therapeutic use/adverse effects
*COVID-19 Drug Treatment
COVID-19/mortality
Treatment Outcome
Randomized Controlled Trials as Topic
SARS-CoV-2

@article {pmid34423546,
year = {2021},
author = {Hamad, N and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Gottlieb, D and Ritchie, D and Harrison, S and Kennedy, G and Watson, AM and Greenwood, M and Doocey, R and Perera, T and Spencer, A and Wong, E and O'Brien, T and Shaw, P and Conyers, R and Milliken, S and Bardy, P and Larsen, S and Ho, PJ and Lai, H and Bajel, A and Butler, J and Tiley, C and D'Rozario, J and Johnston, A and Cochrane, T and Mills, T and Irving, I and Pullon, H and Purtill, D},
title = {Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {8},
pages = {1321-1323},
pmid = {34423546},
issn = {1445-5994},
mesh = {Adult ; Australia/epidemiology ; *COVID-19/prevention & control ; *COVID-19 Vaccines ; Child ; Consensus ; Humans ; New Zealand/epidemiology ; Prospective Studies ; *Transplant Recipients ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Adult
Australia/epidemiology
*COVID-19/prevention & control
*COVID-19 Vaccines
Child
Consensus
Humans
New Zealand/epidemiology
Prospective Studies
*Transplant Recipients
Vaccination

@article {pmid34399446,
year = {2021},
author = {Ku, CR and Jung, KY and Ahn, CH and Moon, JS and Lee, JH and Kim, EH and Kwon, H and Kim, HK and Suh, S and Hong, S and Ha, J and Roh, E and Kim, JH and Kim, MK and , },
title = {COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society.},
journal = {Endocrinology and metabolism (Seoul, Korea)},
volume = {36},
number = {4},
pages = {757-765},
pmid = {34399446},
issn = {2093-5978},
mesh = {COVID-19/epidemiology/immunology/*prevention & control ; COVID-19 Vaccines/administration & dosage/adverse effects/*standards ; *Endocrine System Diseases/epidemiology/immunology ; Endocrinologists/*standards ; Humans ; Practice Guidelines as Topic/standards ; Republic of Korea/epidemiology ; Societies, Medical/*standards ; Vaccination/*standards ; },
abstract = {Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients' health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.},
}

COVID-19/epidemiology/immunology/*prevention & control
COVID-19 Vaccines/administration & dosage/adverse effects/*standards
*Endocrine System Diseases/epidemiology/immunology
Endocrinologists/*standards
Humans
Practice Guidelines as Topic/standards
Republic of Korea/epidemiology
Societies, Medical/*standards
Vaccination/*standards

@article {pmid34310563,
year = {2021},
author = {Caldarola, P and Murrone, A and Roncon, L and Di Pasquale, G and Tavazzi, L and Amodeo, V and Aspromonte, N and Cipriani, M and Di Lenarda, A and Domenicucci, S and Francese, GM and Imazio, M and Scotto di Uccio, F and Urbinati, S and Valente, S and Gulizia, MM and Colivicchi, F and Gabrielli, D},
title = {[ANMCO Position paper: Reorganization of cardiology in the era of the COVID-19 pandemic].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {8},
pages = {610-619},
doi = {10.1714/3641.36216},
pmid = {34310563},
issn = {1972-6481},
mesh = {*COVID-19 ; Cardiology/*organization & administration ; Cardiovascular Diseases/therapy ; Delivery of Health Care/*organization & administration ; Health Personnel/organization & administration ; Humans ; Italy ; National Health Programs/organization & administration ; },
abstract = {The COVID-19 pandemic represents an unprecedented event that has brought deep changes in hospital facilities with reshaping of the health system organization, revealing inadequacies of current hospital and local health systems. When the COVID-19 emergency will end, further evaluation of the national health system, new organization of acute wards, and a further evolution of the entire health system will be needed to improve care during the chronic phase of disease. Therefore, new standards for healthcare personnel, more efficient organization of hospital facilities for patients with acute illnesses, improvement of technological approaches, and better integration between hospital and territorial services should be pursued. With experience derived from the COVID-19 pandemic, new models, paradigms, interventional approaches, values and priorities should be suggested and implemented.},
}

*COVID-19
Cardiology/*organization & administration
Cardiovascular Diseases/therapy
Delivery of Health Care/*organization & administration
Health Personnel/organization & administration
Humans
Italy
National Health Programs/organization & administration

@article {pmid34227785,
year = {2021},
author = {Gnanaraj, JP and Anne, PS and Majella, CM and Durairaj, P and Edwin, R and Kannan, K and Ramachandran, V and Jeyabalan, N and Mohanan, N and Krishnan, S and Somasundaram, S},
title = {Antithrombotic Therapy in COVID-19 - A Scientific Position Statement by Heart Disease Management Program, National Health Mission, Government of Tamil Nadu.},
journal = {The Journal of the Association of Physicians of India},
volume = {69},
number = {1},
pages = {82-87},
pmid = {34227785},
issn = {0004-5772},
mesh = {*COVID-19 ; Disease Management ; *Fibrinolytic Agents ; Government ; Humans ; India ; National Health Programs ; SARS-CoV-2 ; },
}

*COVID-19
Disease Management
*Fibrinolytic Agents
Government
Humans
India
National Health Programs
SARS-CoV-2

@article {pmid34212511,
year = {2021},
author = {Butsch, WS and Hajduk, A and Cardel, MI and Donahoo, WT and Kyle, TK and Stanford, FC and Zeltser, LM and Kotz, CM and Jastreboff, AM},
title = {COVID-19 vaccines are effective in people with obesity: A position statement from The Obesity Society.},
journal = {Obesity (Silver Spring, Md.)},
volume = {29},
number = {10},
pages = {1575-1579},
pmid = {34212511},
issn = {1930-739X},
support = {P30 DK040561/DK/NIDDK NIH HHS/United States ; UL1 TR001863/TR/NCATS NIH HHS/United States ; I01 BX003004/BX/BLRD VA/United States ; P30 DK045735/DK/NIDDK NIH HHS/United States ; I01 BX003687/BX/BLRD VA/United States ; },
mesh = {Adolescent ; Adult ; Aged ; COVID-19/*immunology/*prevention & control/virology ; COVID-19 Vaccines/*immunology ; Clinical Trials as Topic ; Humans ; Middle Aged ; Obesity/*immunology ; SARS-CoV-2/*immunology ; *Societies, Medical ; Young Adult ; },
abstract = {The position statement is issued by The Obesity Society in response to published literature, as well as inquiries made to the Society by patients, providers, Society members, policy makers, and others regarding the efficacy of vaccines in persons with obesity against SARS-CoV-2, the virus that causes COVID-19. The Obesity Society has critically evaluated data from published peer-reviewed literature and briefing documents from Emergency Use Authorization applications submitted by Pfizer-BioNTech, Moderna, and Johnson & Johnson. We conclude that these vaccines are highly efficacious, and their efficacy is not significantly different in people with and without obesity, based on scientific evidence available at the time of publication. The Obesity Society believes there is no definitive way to determine which of these three COVID-19 vaccines is "best" for any weight subpopulation (because of differences in the trial design and outcome measures in the phase 3 trials, elapsed time between doses, and regional differences in the presence of SARS-CoV-2 variants [e.g., South Africa B.1.351 in Johnson & Johnson trial]). All three trials have demonstrated high efficacy against COVID-19-associated hospitalization and death. Therefore, The Obesity Society encourages adults with obesity ≥18 years (≥16 years for Pfizer-BioNTech) to undergo vaccination with any one of the currently available vaccines authorized for emergency use by the US Food and Drug Administration as soon as they are able.},
}

Adolescent
Adult
Aged
COVID-19/*immunology/*prevention & control/virology
COVID-19 Vaccines/*immunology
Clinical Trials as Topic
Humans
Middle Aged
Obesity/*immunology
SARS-CoV-2/*immunology
*Societies, Medical
Young Adult

@article {pmid34180546,
year = {2022},
author = {Korath, ADJ and Janda, J and Untersmayr, E and Sokolowska, M and Feleszko, W and Agache, I and Adel Seida, A and Hartmann, K and Jensen-Jarolim, E and Pali-Schöll, I},
title = {One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2.},
journal = {Allergy},
volume = {77},
number = {1},
pages = {55-71},
pmid = {34180546},
issn = {1398-9995},
support = {//European Academy of Allergy and Clinical Immunology (EAACI)/ ; },
mesh = {Animals ; *COVID-19 ; Humans ; *One Health ; Pandemics ; Quality of Life ; SARS-CoV-2 ; },
abstract = {The latest outbreak of a coronavirus disease in 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evolved into a worldwide pandemic with massive effects on health, quality of life, and economy. Given the short period of time since the outbreak, there are several knowledge gaps on the comparative and zoonotic aspects of this new virus. Within the One Health concept, the current EAACI position paper dwells into the current knowledge on SARS-CoV-2's receptors, symptoms, transmission routes for human and animals living in close vicinity to each other, usefulness of animal models to study this disease and management options to avoid intra- and interspecies transmission. Similar pandemics might appear unexpectedly and more frequently in the near future due to climate change, consumption of exotic foods and drinks, globe-trotter travel possibilities, the growing world population, the decreasing production space, declining room for wildlife and free-ranging animals, and the changed lifestyle including living very close to animals. Therefore, both the society and the health authorities need to be aware and well prepared for similar future situations, and research needs to focus on prevention and fast development of treatment options (medications, vaccines).},
}

Animals
*COVID-19
Humans
*One Health
Pandemics
Quality of Life
SARS-CoV-2

@article {pmid34170086,
year = {2021},
author = {Richter, D and Guasti, L and Koehler, F and Squizzato, A and Nistri, S and Christodorescu, R and Dievart, F and Gaudio, G and Asteggiano, R and Ferrini, M},
title = {Late phase of COVID-19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice.},
journal = {ESC heart failure},
volume = {8},
number = {5},
pages = {3483-3494},
pmid = {34170086},
issn = {2055-5822},
mesh = {*COVID-19/complications ; *Cardiology ; Humans ; Pandemics ; SARS-CoV-2 ; Post-Acute COVID-19 Syndrome ; },
abstract = {Cardiovascular (CV) engagement in coronavirus disease 2019 (COVID-19) is a huge determinant of prognosis during the acute phase of the disease. However, little is known about the potential chronic implications of the late phase of COVID-19 and about the appropriate approach to these patients. Heart failure, type 1 and type 2 myocardial infarction, arrhythmias, myocarditis, pulmonary fibrosis, and thrombosis have been shown to be related to severe acute respiratory syndrome coronavirus 2 infection, and a 'long COVID-19' illness has been recognized with fatigue, chest pain, and dyspnoea among the most frequent symptoms reported after discharge from hospital. This paper focuses on some open questions that cardiologists are going to face during the next months in a general cardiology outpatient clinic, in particular how to evaluate a 'post-COVID' patient during follow-up of CV complications of the acute phase and how to manage new CV symptoms that could be the consequence, at least in part, of heart/vessels and/or lung involvement of the previous virus infection. Present symptoms and signs, history of previous CV disease (both preceding COVID-19 and occurring during viral infection), and specific laboratory and imaging measurements during the acute phase may be of interest in focusing on how to approach the clinical evaluation of a post-COVID patient and how to integrate in our standard of care the new information on COVID-19, possibly in a multidisciplinary view. Dealing with the increased COVID-associated CV risk burden and becoming acquainted with potential new e-cardiology approaches aimed at integrating the cardiology practice are relevant new challenges brought by severe acute respiratory syndrome coronavirus 2 infection and its sequelae.},
}

*COVID-19/complications
*Cardiology
Humans
Pandemics
SARS-CoV-2
Post-Acute COVID-19 Syndrome

@article {pmid34155756,
year = {2021},
author = {Kanjanapan, Y and Blinman, P and Underhill, C and Karikios, D and Segelov, E and Yip, D},
title = {Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours.},
journal = {Internal medicine journal},
volume = {51},
number = {6},
pages = {955-959},
pmid = {34155756},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Humans ; Medical Oncology ; *Neoplasms/epidemiology/therapy ; SARS-CoV-2 ; Vaccination ; },
abstract = {People with cancer are vulnerable to increased morbidity and mortality from the coronavirus disease 2019 (COVID-19). COVID-19 vaccination is key to protecting the population of people with cancer from adverse outcomes of SARS-CoV-2 infection. The Medical Oncology Group of Australia aimed to address the considerations around COVID-19 vaccination in people with cancer, in particular, safety and efficacy of vaccination. The assessment of patients with generalised allergic reaction to anti-cancer therapy containing vaccine components and practical implementation of vaccination of people on active anti-cancer therapy are also discussed.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Humans
Medical Oncology
*Neoplasms/epidemiology/therapy
SARS-CoV-2
Vaccination

@article {pmid34142284,
year = {2022},
author = {Testino, G and Vignoli, T and Patussi, V and Allosio, P and Amendola, MF and Aricò, S and Baselice, A and Balbinot, P and Campanile, V and Fanucchi, T and Greco, G and Macciò, L and Meneguzzi, C and Mioni, D and Palmieri, VO and Parisi, M and Renzetti, D and Rossin, R and Gandin, C and Bottaro, LC and Bernardi, M and Addolorato, G and Lungaro, L and Zoli, G and Scafato, E and Caputo, F},
title = {Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA).},
journal = {Digestive diseases and sciences},
volume = {67},
number = {6},
pages = {1975-1986},
pmid = {34142284},
issn = {1573-2568},
mesh = {*Alcoholism/complications/epidemiology/therapy ; *COVID-19 ; Communicable Disease Control ; Humans ; *Liver Diseases, Alcoholic/epidemiology/therapy ; Pandemics ; },
abstract = {BACKGROUND: Coronavirus Disease 2019 (COVID-19), firstly reported in China last November 2019, became a global pandemic. It has been shown that periods of isolation may induce a spike in alcohol use disorder (AUD). In addition, alcohol-related liver disease (ALD) is the most common consequence of excessive alcohol consumption worldwide. Moreover, liver impairment has also been reported as a common manifestation of COVID-19.

AIMS: The aim of our position paper was to consider some critical issues regarding the management of ALD in patients with AUD in the era of COVID-19.

METHODS: A panel of experts of the Italian Society of Alcohology (SIA) met via "conference calls" during the lockdown period to draft the SIA's criteria for the management of ALD in patients with COVID-19 as follows: (a) liver injury in patients with ALD and COVID-19 infection; (b) toxicity to the liver of the drugs currently tested to treat COVID-19 and the pharmacological interaction between medications used to treat AUD and to treat COVID-19; (c) reorganization of the management of compensated and decompensated ALD and liver transplantation in the COVID-19 era.

RESULTS AND CONCLUSIONS: The COVID-19 pandemic has rapidly carried us toward a new governance scenario of AUD and ALD which necessarily requires an in-depth review of the management of these diseases with a new safe approach (management of out-patients and in-patients following new rules of safety, telemedicine, telehealth, call meetings with clinicians, nurses, patients, and caregivers) without losing the therapeutic efficacy of multidisciplinary treatment.},
}

*Alcoholism/complications/epidemiology/therapy
*COVID-19
Communicable Disease Control
Humans
*Liver Diseases, Alcoholic/epidemiology/therapy
Pandemics

@article {pmid34133609,
year = {2021},
author = {Colombo, CSSS and Leitão, MB and Avanza Junior, AC and Borges, SF and Silveira, ADD and Braga, F and Camarozano, AC and Kopiler, DA and Lazzoli, JK and Freitas, OGA and Grossman, GB and Milani, M and Nunes, MB and Ritt, LEF and Sellera, CAC and Ghorayeb, N},
title = {Position Statement on Post-COVID-19 Cardiovascular Preparticipation Screening: Guidance for Returning to Physical Exercise and Sports - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {116},
number = {6},
pages = {1213-1226},
pmid = {34133609},
issn = {1678-4170},
mesh = {*COVID-19 ; *Cardiovascular Diseases/diagnosis/prevention & control ; Death, Sudden, Cardiac/prevention & control ; Exercise ; Humans ; Mass Screening ; Physical Examination ; SARS-CoV-2 ; *Sports ; *Sports Medicine ; },
}

*COVID-19
*Cardiovascular Diseases/diagnosis/prevention & control
Death, Sudden, Cardiac/prevention & control
Exercise
Humans
Mass Screening
Physical Examination
SARS-CoV-2
*Sports
*Sports Medicine

@article {pmid34100388,
year = {2021},
author = {Alqahtani, SA and Barry, M and Memish, Z and Hashim, A and Alfares, MA and Alghamdi, SA and Al-Hamoudi, WK and Al-Judaibi, B and Alhazzani, W and Al-Tawfiq, JA and Abaalkhail, F},
title = {Use of COVID-19 vaccines in patients with liver disease and post-liver transplantation: Position statement of the Saudi association for the study of liver diseases and transplantation.},
journal = {Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association},
volume = {27},
number = {4},
pages = {201-207},
pmid = {34100388},
issn = {1998-4049},
mesh = {BNT162 Vaccine ; *COVID-19 ; COVID-19 Vaccines ; ChAdOx1 nCoV-19 ; Humans ; *Liver Diseases ; *Liver Transplantation ; SARS-CoV-2 ; Saudi Arabia ; },
abstract = {Patients with chronic liver disease (CLD) and liver transplant recipients are at increased risk of morbidity and mortality from coronavirus disease 2019 (COVID-19). Although several studies demonstrated the safety and efficacy of COVID-19 vaccines in the general population, data in CLD patients and liver transplant recipients are lacking. Two COVID-19 vaccines were approved by the Saudi Food and Drug Authority and rolled out to several million recipients in Saudi Arabia. These vaccines are mRNA-based vaccine BNT162b2 from Pfizer/BioNTech and adenovirus-based AZD1222 from Oxford/AstraZeneca from three manufacturing sites (EU Nodes, Serum Institute of India, and South Korea Bio). The Saudi Association for the Study of Liver diseases and Transplantation (SASLT) has reviewed the available evidence and issued interim recommendations for COVID-19 vaccination in CLD and liver transplant recipients. Since there is no evidence contradicting the safety and immunogenicity of the currently approved COVID-19 vaccines in patients with CLD and hepatobiliary cancer and liver transplant recipients, the SASLT recommends vaccination in those patient populations. CLD and hepatobiliary cancer patients and liver transplant recipients should be prioritized depending on the risk factors for severe COVID-19. In transplant recipients, the optimal timing of vaccination remains unknown; however, immunization is recommended after the initial immunosuppression phase. Patients with CLD and liver transplant candidates or recipients should be closely monitored after COVID-19 vaccination. These patient populations should be included in future clinical trials to provide further evidence on the efficacy and safety of COVID-19 vaccines.},
}

BNT162 Vaccine
*COVID-19
COVID-19 Vaccines
ChAdOx1 nCoV-19
Humans
*Liver Diseases
*Liver Transplantation
SARS-CoV-2
Saudi Arabia

@article {pmid34059190,
year = {2021},
author = {Prati, D and Fiorin, F and Berti, P and De Silvestro, G and Accorsi, P and Ostuni, A and , },
title = {Position paper on the use of COVID-19 convalescent plasma: an update.},
journal = {Blood transfusion = Trasfusione del sangue},
volume = {19},
number = {4},
pages = {277-280},
pmid = {34059190},
issn = {2385-2070},
mesh = {COVID-19/blood/*therapy ; *Consensus ; Humans ; Immunization, Passive/standards ; Inpatients ; Italy ; Meta-Analysis as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome ; COVID-19 Serotherapy ; },
}

COVID-19/blood/*therapy
*Consensus
Humans
Immunization, Passive/standards
Inpatients
Italy
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Treatment Outcome
COVID-19 Serotherapy

@article {pmid34052501,
year = {2021},
author = {Al-Motlaq, M and Neill, S and Foster, MJ and Coyne, I and Houghton, D and Angelhoff, C and Rising-Holmström, M and Majamanda, M},
title = {Position Statement of the International Network for Child and Family Centered Care: Child and Family Centred Care during the COVID19 Pandemic.},
journal = {Journal of pediatric nursing},
volume = {61},
number = {},
pages = {140-143},
pmid = {34052501},
issn = {1532-8449},
mesh = {*COVID-19 ; Child ; Family ; Humans ; Pandemics ; Patient-Centered Care ; SARS-CoV-2 ; },
abstract = {It is the position of the International Network for Child and Family Centered Care (INCFCC) that COVID19 restrictions pose tremendous challenges for the health care team in their efforts to provide child and family centered care (CFCC). COVID-19 restrictions impact on the family's right to be presernt with their ill child and to contribute to the caring process. A limited number of articles have discussed challenges about the successful delivery of CFCC during the COVID-19 pandemic. Based on current literature, the INCFCC stresses the need for continuous facilitation implementation of child and family centred care as, it is essential for children's physical and psychological wellbeing. Furthermore we believe that the families' presence and participation holds more benefits than risks to the health of children, their families, and the health care team.},
}

*COVID-19
Child
Family
Humans
Pandemics
Patient-Centered Care
SARS-CoV-2

@article {pmid34048585,
year = {2021},
author = {Bean, MK and Adams, EL and Buscemi, J and Ford, S and Wischenka, D and Behrman, P and Wilson, DK and Gladstone, TRG and Fitzgibbon, ML},
title = {Society of Behavioral Medicine (SBM) Position Statement: increase access to mental health services due to COVID-19-related parent and family stress.},
journal = {Translational behavioral medicine},
volume = {11},
number = {8},
pages = {1635-1637},
pmid = {34048585},
issn = {1613-9860},
support = {T32 CA093423/CA/NCI NIH HHS/United States ; 2T32CA093423//National Cancer Institute at the National Institutes of Health/ ; 2T32 CA093423/NH/NIH HHS/United States ; },
mesh = {*Behavioral Medicine ; *COVID-19 ; Child ; Humans ; *Mental Health Services ; Parents ; SARS-CoV-2 ; United States/epidemiology ; },
abstract = {COVID-19 has caused drastic increases in family stress contributing to deleterious social and emotional ramifications. Before COVID-19, millions of Americans lacked access to mental health resources, and now in the midst of a global pandemic, resources are more limited in times of greater need. In March 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act provided funding for mental health reforms; yet many barriers remained to receiving sufficient care. In February 2021, the Society of Behavioral Medicine recommended federal legislators expand Community Behavioral Healthcare Centers, increase funding for Federally Qualified Healthcare Centers and School Based Health Centers, incentivize providers to accept Medicaid, and institute more statewide licensing flexibilities to expand the reach of mental health care. In March 2021, the American Rescue Plan was signed into law and provided an additional ~$4 billion in funding for community mental health services, implementing substance abuse prevention and treatment programs, increasing the behavioral health workforce, promoting behavioral telehealth within primary care, increasing school-based mental health services, implementing suicide prevention programs, and improving services for traumatized families. This significant investment in parents and children's mental health is a tremendous step in the right direction and provides reassurance that relief is underway. Ongoing surveillance of the programmatic and clinical outcomes that result from these new policy reforms will be important for identifying areas that may need continual support as our nation recovers from COVID-19.},
}

*Behavioral Medicine
*COVID-19
Child
Humans
*Mental Health Services
Parents
SARS-CoV-2
United States/epidemiology

@article {pmid34047035,
year = {2021},
author = {McCaughan, G and Di Ciaccio, P and Ananda-Rajah, M and Gilroy, N and MacIntyre, R and Teh, B and Weinkove, R and Curnow, J and Szer, J and Enjeti, AK and Ross, DM and Mulligan, S and Trotman, J and Dickinson, M and Quach, H and Choi, P and Polizzotto, MN and Tam, CS and Ho, PJ and Ku, M and Gregory, G and Gangatharan, S and Hapgood, G and Cochrane, T and Cheah, C and Gibbs, S and Wei, A and Johnston, A and Greenwood, M and Prince, HM and Latimer, M and Berkahn, L and Wight, J and Armytage, T and Hamad, N},
title = {COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement.},
journal = {Internal medicine journal},
volume = {51},
number = {5},
pages = {763-768},
pmid = {34047035},
issn = {1445-5994},
mesh = {Australia/epidemiology ; *COVID-19 ; COVID-19 Vaccines ; Consensus ; *Hematology ; Humans ; New Zealand/epidemiology ; Prospective Studies ; SARS-CoV-2 ; Vaccination ; },
abstract = {Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.},
}

Australia/epidemiology
*COVID-19
COVID-19 Vaccines
Consensus
*Hematology
Humans
New Zealand/epidemiology
Prospective Studies
SARS-CoV-2
Vaccination

@article {pmid34030157,
year = {2021},
author = {Exten, C and Pinto, CN and Gaynor, AM and Meyerson, B and Griner, SB and Van Der Pol, B and , },
title = {Direct-to-Consumer Sexually Transmitted Infection Testing Services: A Position Statement from the American Sexually Transmitted Diseases Association.},
journal = {Sexually transmitted diseases},
volume = {48},
number = {11},
pages = {e155-e159},
pmid = {34030157},
issn = {1537-4521},
mesh = {*COVID-19 ; Humans ; Pandemics ; SARS-CoV-2 ; *Sexually Transmitted Diseases/diagnosis/epidemiology ; Specimen Handling ; United States/epidemiology ; },
abstract = {Direct-to-consumer test services have gained popularity for sexually transmitted infections in recent years, with substantially increased use as a result of the SARS-CoV-2 (CoVID-19) global pandemic. This method of access has been variously known as "self-testing," "home testing," and "direct access testing." Although these online services may be offered through different mechanisms, here we focus on those that are consumer-driven and require self-collected samples, and sample shipment to a centralized laboratory without involvement of health care providers and/or local health departments. We provide the American Sexually Transmitted Diseases Association's position on utilization of these services and recommendations for both consumers and health care providers.},
}

*COVID-19
Humans
Pandemics
SARS-CoV-2
*Sexually Transmitted Diseases/diagnosis/epidemiology
Specimen Handling
United States/epidemiology

@article {pmid33976449,
year = {2020},
author = {Awuku, YA and Jibril, AT and Bockarie, AS and Duah, A and Tachi, K and Agyei-Nkansah, A and Afihene, MY},
title = {Gastroenterology practice in the COVID-19 era: Ghana Association for the Study of Liver and Digestive Diseases (GASLIDD) position statement.},
journal = {Ghana medical journal},
volume = {54},
number = {4 Suppl},
pages = {104-106},
pmid = {33976449},
issn = {2616-163X},
mesh = {COVID-19/*prevention & control ; Endoscopy, Gastrointestinal/*standards ; Gastroenterology/*standards ; Ghana ; Humans ; Infection Control/*standards ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {UNLABELLED: The COVID-19 pandemic has impacted healthcare negatively across the globe. The practice of gastroenterology has been affected especially gastrointestinal (GI) endoscopy which is considered high risk for transmission of the virus. As a community of practitioners there is the need to share information and make evidence-based statements to guide GI practice in Ghana. This GASLIDD position statement based on the growing and rapidly evolving body of knowledge is to provide up to date information on the COVID-19 disease and guidance for the practice of gastroenterology in Ghana and beyond. It is to help the GI community of practice to maintain the highest level of health delivery and safety for our patients, staff, community and GI practitioners.

FUNDING: Self-funded.},
}

COVID-19/*prevention & control
Endoscopy, Gastrointestinal/*standards
Gastroenterology/*standards
Ghana
Humans
Infection Control/*standards
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid33960979,
year = {2021},
author = {Indolfi, C and Barillà, F and Basso, C and Ciccone, MM and Curcio, A and Mancone, M and Mercuro, G and Muscoli, S and Nodari, S and Pedrinelli, R and Romeo, F and Sinagra, G and Filardi, PP},
title = {[Position paper of the Italian Society of Cardiology (SIC) on COVID-19 vaccine priority in patients with cardiovascular diseases].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {22},
number = {5},
pages = {363-375},
doi = {10.1714/3592.35745},
pmid = {33960979},
issn = {1972-6481},
mesh = {Age Factors ; Animals ; COVID-19/epidemiology/mortality/*prevention & control ; COVID-19 Vaccines/*administration & dosage ; Cardiology ; Cardiovascular Diseases/*complications ; *Consensus ; Coronary Disease/complications ; Disease Vectors ; Heart Failure/complications ; Heart Transplantation ; Heart Valve Diseases/complications ; Humans ; Hypertension, Pulmonary/complications ; Italy/epidemiology ; Prognosis ; Renal Insufficiency/complications ; SARS-CoV-2/immunology ; Societies, Medical ; Vaccines, Synthetic/administration & dosage ; mRNA Vaccines ; },
abstract = {In over a year, the COVID-19 pandemic caused 2.69 million deaths and 122 million infections. Social isolation and distancing measures have been the only prevention available for months. Scientific research has done a great deal of work, developing in a few months safe and effective vaccines against COVID-19. In the European Union, nowadays, four vaccines have been authorized for use: Pfizer-BioNTech, Moderna, ChAdOx1 (AstraZeneca/Oxford), Janssen (Johnson & Johnson), and three others are currently under rolling review.Vaccine allocation policy is crucial to optimize the advantage of treatment preferring people with the highest risk of contagion. These days the priority in the vaccination program is of particular importance since it has become clear that the number of vaccines is not sufficient for the entire Italian population in the short term. Cardiovascular diseases are frequently associated with severe COVID-19 infections, leading to the worst prognosis. The elderly population suffering from cardiovascular diseases is, therefore, to be considered a particularly vulnerable population. However, age cannot be considered the only discriminating factor because in the young-adult population suffering from severe forms of heart disease, the prognosis, if affected by COVID-19, is particularly ominous and these patients should have priority access to the vaccination program. The aim of this position paper is to establish a consensus on a priority in the vaccination of COVID-19 among subjects suffering from different cardiovascular diseases.},
}

Age Factors
Animals
COVID-19/epidemiology/mortality/*prevention & control
COVID-19 Vaccines/*administration & dosage
Cardiology
Cardiovascular Diseases/*complications
*Consensus
Coronary Disease/complications
Disease Vectors
Heart Failure/complications
Heart Transplantation
Heart Valve Diseases/complications
Humans
Hypertension, Pulmonary/complications
Italy/epidemiology
Prognosis
Renal Insufficiency/complications
SARS-CoV-2/immunology
Societies, Medical
Vaccines, Synthetic/administration & dosage
mRNA Vaccines

@article {pmid33941488,
year = {2021},
author = {Russo, FP and Piano, S and Bruno, R and Burra, P and Puoti, M and Masarone, M and Montagnese, S and Ponziani, FR and Petta, S and Aghemo, A and , },
title = {Italian association for the study of the liver position statement on SARS-CoV2 vaccination.},
journal = {Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
volume = {53},
number = {6},
pages = {677-681},
pmid = {33941488},
issn = {1878-3562},
mesh = {*COVID-19/epidemiology/prevention & control ; *COVID-19 Vaccines/classification/pharmacology ; Humans ; *Immunization Programs/methods/organization & administration ; Immunosuppressive Agents/therapeutic use ; Italy/epidemiology ; *Liver Diseases/immunology/therapy ; Liver Transplantation ; Patient Safety ; Patient Selection ; Risk Adjustment/*methods ; Risk Assessment ; SARS-CoV-2/immunology ; Transplant Recipients ; Treatment Outcome ; },
abstract = {The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver disease, a possible priority for vaccination for this category of patients.},
}

*COVID-19/epidemiology/prevention & control
*COVID-19 Vaccines/classification/pharmacology
Humans
*Immunization Programs/methods/organization & administration
Immunosuppressive Agents/therapeutic use
Italy/epidemiology
*Liver Diseases/immunology/therapy
Liver Transplantation
Patient Safety
Patient Selection
Risk Adjustment/*methods
Risk Assessment
SARS-CoV-2/immunology
Transplant Recipients
Treatment Outcome

@article {pmid33909805,
year = {2021},
author = {Queiroz, NSF and Teixeira, FV and Freire, CCF and Motta, MP and Vasconcellos, MAM and Chebli, LA and Saad-Hossne, R and , },
title = {BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.},
journal = {Arquivos de gastroenterologia},
volume = {58},
number = {1},
pages = {1-4},
doi = {10.1590/S0004-2803.202100000-02},
pmid = {33909805},
issn = {1678-4219},
mesh = {Brazil ; *COVID-19 ; COVID-19 Vaccines ; Humans ; *Inflammatory Bowel Diseases ; Pandemics ; RNA, Viral ; SARS-CoV-2 ; Vaccination ; },
abstract = {Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.},
}

Brazil
*COVID-19
COVID-19 Vaccines
Humans
*Inflammatory Bowel Diseases
Pandemics
RNA, Viral
SARS-CoV-2
Vaccination

@article {pmid33861837,
year = {2020},
author = {Álvarez Z, P and Larios G, G and Toro R, L and Acevedo A, V and Arancibia G, F and Cárdenas M, L and Fernández C, C},
title = {[Recommendation for the recognition, management and follow up of cardiovascular compromise in patients with Pediatric Multisystemic Inflammatory Syndrome associated with COVID-19 (PIMS-CT). Position statement of Chilean Scientific Societies].},
journal = {Revista chilena de pediatria},
volume = {91},
number = {6},
pages = {982-990},
doi = {10.32641/rchped.vi91i6.3215},
pmid = {33861837},
issn = {0717-6228},
mesh = {Biomarkers/metabolism ; COVID-19/diagnosis/physiopathology/*therapy ; Cardiovascular Diseases/diagnosis/therapy/*virology ; Child ; Chile ; Humans ; Mucocutaneous Lymph Node Syndrome/therapy/virology ; Patient Care Team/organization & administration ; Shock/therapy/virology ; Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy ; },
abstract = {Since the onset of the SARS-CoV-2 pandemic, the pediatric population has been less affected by the disease both in frequency and severity. However, since April cases of variable presentation and severity characterized by inflammatory phenomena that affect multiple organs have been reported, a condition called Multisystem Inflammatory Syndrome in Children (MIS-C). The literature has reported frequent cardiac involvement, up to 80%. This is characterized by myocardial injury with a significant increase of biomarkers such as serum troponins I and T, BNP, or NT-ProBNP coupled with varying degrees of ventricular dysfunction, pericarditis, valvulitis, and arrhythmias. Coronary compromise has also been described, which can occur in up to 23% of cases, and ranges from dila tations to aneurysms. Inpatient and outpatient cardiology follow-up has been systematized based on the clinical phenotypes such as myocardial injury (myocarditis, valvulitis, pericarditis), shock (usua lly vasoplegic), Kawasaki disease-type manifestations, and those MIS-C that do not comply with the clinic of the previous three. This last group represents the main challenge in the short-, medium- and long-term follow-up, therefore, it is necessary a multidisciplinary team for managing these patients. Considering the high frequency of cardiac compromise in MIS-C, and the importance of reaching a consensus regarding its management and follow-up, we present these recommendations according to the current state of knowledge regarding this recently described pathology.},
}

Biomarkers/metabolism
COVID-19/diagnosis/physiopathology/*therapy
Cardiovascular Diseases/diagnosis/therapy/*virology
Child
Chile
Humans
Mucocutaneous Lymph Node Syndrome/therapy/virology
Patient Care Team/organization & administration
Shock/therapy/virology
Systemic Inflammatory Response Syndrome/diagnosis/physiopathology/*therapy

@article {pmid33839767,
year = {2021},
author = {Badimon, L and Robinson, EL and Jusic, A and Carpusca, I and deWindt, LJ and Emanueli, C and Ferdinandy, P and Gu, W and Gyöngyösi, M and Hackl, M and Karaduzovic-Hadziabdic, K and Lustrek, M and Martelli, F and Nham, E and Potočnjak, I and Satagopam, V and Schneider, R and Thum, T and Devaux, Y},
title = {Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129.},
journal = {Cardiovascular research},
volume = {117},
number = {8},
pages = {1823-1840},
pmid = {33839767},
issn = {1755-3245},
support = {CH/15/1/31199/BHF_/British Heart Foundation/United Kingdom ; RG/20/9/35101/BHF_/British Heart Foundation/United Kingdom ; },
mesh = {Artificial Intelligence/*economics ; Biomarkers/*analysis ; COVID-19/*diagnosis ; Cardiovascular Diseases/diagnosis/genetics ; Cardiovascular System/virology ; Humans ; Quality of Life ; RNA/*genetics ; SARS-CoV-2/pathogenicity ; },
abstract = {The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of 8 February 2020 and causing more than 2.3 million deaths according to the World Health Organization (WHO). Not only affecting the lungs but also provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events, such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast-track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision-making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation, and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts, and the added value of artificial intelligence to achieve reliable advances.},
}

Artificial Intelligence/*economics
Biomarkers/*analysis
COVID-19/*diagnosis
Cardiovascular Diseases/diagnosis/genetics
Cardiovascular System/virology
Humans
Quality of Life
RNA/*genetics
SARS-CoV-2/pathogenicity

@article {pmid33820898,
year = {2021},
author = {Rodrigues, AM and Romeu, JC and Canas da Silva, J and Tavares-Costa, J and Faustino, A and Vaz, C and Pereira da Silva, JA and Canhão, H},
title = {Osteoporosis management during the COVID-19 pandemic - Position paper.},
journal = {Acta reumatologica portuguesa},
volume = {46},
number = {1},
pages = {55-57},
pmid = {33820898},
issn = {2184-8777},
mesh = {*COVID-19 ; Humans ; Osteoporosis/*therapy ; },
abstract = {COVID-19 pandemic significantly increased the already large number of victims of osteoporosis in Portugal. Osteoporosis outpatient clinics were either closed or had limited presential appointments. Many hospitals reduced orthopaedic services to make space for patients with COVID-19. In addition, the volunteer or forced sedentarism, as imposed by the pandemic, increased the risk of falls and fractures drastically. It urges to intensify the current efforts to improve the management of bone health and to prioritize fragility fracture care and prevention. This paper addresses the challenges in osteoporosis management during the COVID-19 pandemic and provides guidance on osteoporosis management. This position paper is a joint initiative of several health professionals and patients dedicated to osteoporosis.},
}

*COVID-19
Humans
Osteoporosis/*therapy

@article {pmid33780557,
year = {2021},
author = {Arenbergerova, M and Lallas, A and Nagore, E and Rudnicka, L and Forsea, AM and Pasek, M and Meier, F and Peris, K and Olah, J and Posch, C},
title = {Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {7},
pages = {e427-e428},
pmid = {33780557},
issn = {1468-3083},
support = {PROGRES Q28//Charles University, Prague, Czech Republic/ ; },
mesh = {*COVID-19 ; Humans ; *Melanoma/therapy ; SARS-CoV-2 ; *Skin Neoplasms/therapy ; },
}

*COVID-19
Humans
*Melanoma/therapy
SARS-CoV-2
*Skin Neoplasms/therapy

@article {pmid33752263,
year = {2021},
author = {Ring, J and Worm, M and Wollenberg, A and Thyssen, JP and Jakob, T and Klimek, L and Bangert, C and Barbarot, S and Bieber, T and de Bruin-Weller, MS and Chernyshov, PV and Christen-Zaech, S and Cork, M and Darsow, U and Flohr, C and Fölster-Holst, R and Gelmetti, C and Gieler, U and Gutermuth, J and Heratizadeh, A and Hijnen, DJ and von Kobyletzki, LB and Kunz, B and Paul, C and De Raeve, L and Seneschal, J and Simon, D and Spuls, PI and Stalder, JF and Svensson, A and Szalai, Z and Taieb, A and Torrelo, A and Trzeciak, M and Vestergaard, C and Werfel, T and Weidinger, S and Deleuran, M},
title = {Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {6},
pages = {e362-e365},
pmid = {33752263},
issn = {1468-3083},
mesh = {*Anaphylaxis ; *COVID-19 ; COVID-19 Vaccines ; *Dermatitis, Atopic/prevention & control ; Humans ; SARS-CoV-2 ; *Vaccines ; },
}

*Anaphylaxis
*COVID-19
COVID-19 Vaccines
*Dermatitis, Atopic/prevention & control
Humans
SARS-CoV-2
*Vaccines

@article {pmid33642133,
year = {2021},
author = {Tarazona-Santabalbina, FJ and Cuadra, L and Cancio, JM and Carbonell, FR and Garrote, JMP and Casas-Herrero, Á and Martínez-Velilla, N and Serra-Rexach, JA and Formiga, F},
title = {VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.},
journal = {Revista espanola de geriatria y gerontologia},
volume = {56},
number = {3},
pages = {177-182},
pmid = {33642133},
issn = {1578-1747},
mesh = {Aged ; COVID-19/complications/immunology/prevention & control/*therapy ; *Cytokine Release Syndrome/prevention & control ; *Dietary Supplements ; *Geriatrics ; Humans ; Receptors, Calcitriol/metabolism ; Societies, Medical ; Spain ; Vitamin D/*administration & dosage/immunology ; Vitamin D Deficiency/complications/*therapy ; Vitamins/*administration & dosage/immunology ; },
abstract = {The coronavirus disease 2019 (COVID-19) produces severe respiratory symptoms such as bilateral pneumonia associated to a high morbidity and mortality, especially in patients of advanced age. Vitamin D deficiency has been reported in several chronic conditions associated with increased inflammation and dysregulation of the immune system. Vitamin D in modulates immune function too. Vitamin D receptor (VDR) is expressed by most immune cells, including B and T lymphocytes, monocytes, macrophages, and dendritic cells and the signalling of vitamin D and VDR together has an anti-inflammatory effect. Some studies have reported that vitamin D treatment could be useful for the prevention and treatment of COVID-19 because vitamin D plays an important role as a modulator of immunocompetence. Over the last few months, some studies have hypothesized the possible beneficial effect of vitamin D supplementation in patients with COVID-19 in order to improve the immune balance and prevent the hyperinflammatory cytokine storm. Some preliminary studies have already shown promising results with vitamin D supplementation in hospitalized COVID-19 patients. Vitamin D should be administered daily until adequate levels are achieved due to vitamin D behaves as a negative acute phase reactant (APR). Despite the lack of evidence on specific doses of vitamin D to treat COVID-19 in older adults, authors consider it is necessary to standardize the use in clinical practice. These recommendations advice supplement vitamin D in a protocoled fashion based on expert opinions, level of evidence 5.},
}

Aged
COVID-19/complications/immunology/prevention & control/*therapy
*Cytokine Release Syndrome/prevention & control
*Dietary Supplements
*Geriatrics
Humans
Receptors, Calcitriol/metabolism
Societies, Medical
Spain
Vitamin D/*administration & dosage/immunology
Vitamin D Deficiency/complications/*therapy
Vitamins/*administration & dosage/immunology

@article {pmid33533553,
year = {2021},
author = {Beecker, J and Papp, KA and Dutz, J and Vender, RB and Gniadecki, R and Cooper, C and Gisondi, P and Gooderham, M and Hong, CH and Kirchhof, MG and Lynde, CW and Maari, C and Poulin, Y and Puig, L},
title = {Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond.},
journal = {Journal of the European Academy of Dermatology and Venereology : JEADV},
volume = {35},
number = {4},
pages = {797-806},
pmid = {33533553},
issn = {1468-3083},
mesh = {COVID-19/complications/*epidemiology/therapy ; Dermatitis/*therapy ; Humans ; *Immunotherapy ; Practice Patterns, Physicians' ; Risk Assessment ; },
abstract = {Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel RNA virus that was declared a global pandemic on 11 March 2020. The efficiency of infection with SARS-CoV-2 is reflected by its rapid global spread. The SARS-CoV-2 pandemic has implications for patients with inflammatory skin diseases on systemic immunotherapy who may be at increased risk of infection or more severe infection. This position paper is a focused examination of current evidence considering the mechanisms of action of immunotherapeutic drugs in relation to immune response to SARS-CoV-2. We aim to provide practical guidance for dermatologists managing patients with inflammatory skin conditions on systemic therapies during the current pandemic and beyond. Considering the limited and rapidly evolving evidence, mechanisms of action of therapies, and current knowledge of SARS-CoV-2 infection, we propose that systemic immunotherapy can be continued, with special considerations for at risk patients or those presenting with symptoms.},
}

COVID-19/complications/*epidemiology/therapy
Dermatitis/*therapy
Humans
*Immunotherapy
Practice Patterns, Physicians'
Risk Assessment

@article {pmid33518409,
year = {2021},
author = {Zimmerman, E and Martins, NN and Verheijen, RHM and Mahmood, T},
title = {EBCOG position statement - Simulation-based training for obstetrics and gynaecology during the COVID-19 pandemic.},
journal = {European journal of obstetrics, gynecology, and reproductive biology},
volume = {258},
number = {},
pages = {457-458},
pmid = {33518409},
issn = {1872-7654},
mesh = {COVID-19/epidemiology ; Curriculum ; Female ; Gynecology/*education ; Humans ; Obstetrics/*education ; Pandemics ; Pregnancy ; SARS-CoV-2 ; Simulation Training/*standards ; },
abstract = {The specialty of Obstetrics and Gynaecology has been on the forefront of introducing simulation in post graduate education for the past two decades. Simulation training is known to enhance psychomotor skills and is considered an important step in the transition from classroom learning to clinical practice. Training on simulators allows trainees to acquire basic skills before getting involved in day to day care in real life situations. Clinical circumstances around the COVID 19 pandemic have highlighted the key importance of simulation training in delivering post graduate curriculum.},
}

COVID-19/epidemiology
Curriculum
Female
Gynecology/*education
Humans
Obstetrics/*education
Pandemics
Pregnancy
SARS-CoV-2
Simulation Training/*standards

@article {pmid33495916,
year = {2021},
author = {Torres-Naranjo, F and De la Peña-Rodríguez, P and López-Cervantes, RE and Morales-Torres, J and Morales-Vargas, J and Gutiérrez-Hermosillo, H and Guzmán-Rico, AC and González-Mendoza, RG and Rueda Plata, PN and Flores Castro, M and Celis Gonzalez, C and Espinosa Morales, R and Quintero Hernández, S and López-Taylor, JR},
title = {Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.},
journal = {Archives of osteoporosis},
volume = {16},
number = {1},
pages = {18},
pmid = {33495916},
issn = {1862-3514},
mesh = {Aged ; *COVID-19 ; Humans ; *Medicine ; *Orthopedics ; *Osteoporosis/epidemiology/therapy ; Pandemics ; SARS-CoV-2 ; *Traumatology ; },
abstract = {UNLABELLED: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. This joint position statement of Latin American Medical Societies provides an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

BACKGROUND: Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. Characterized by high contagiousness, significative morbidity, and mortality in a segment of those infected, it has overwhelmed health services and forced to redirect resources to the emergency while impacting the attention of acute non-COVID-19 and many chronic conditions.

OBJECTIVE: The objective of this study is to provide an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis.

METHODS: A task force, of bone specialists with a wide range of disciplines in the field of osteoporosis and fragility fracture, was convened with the representation of several professional associations, namely, the Mexican Association of Bone and Mineral Metabolism (AMMOM), the National College of Geriatric Medicine (CONAMEGER), the Latin American Federation of Endocrinology (FELAEN), the Mexican Federation of Colleges of Obstetrics and Gynecology (FEMECOG), the Mexican Federation of Colleges of Orthopedics and Traumatology (FEMECOT), and the Institute of Applied Sciences for Physical Activity and Sports of the University of Guadalajara (ICAAFYD). Clinical evidence was collated, and an evidence report was rapidly generated and disseminated. After finding the gaps in the available evidence, a consensus opinion of experts was made. The resulting draft was reviewed and modified accordingly, in 4 rounds, by the participants.

RESULTS: The task force approved the initial guidance statements, with moderate and high consensus. These were combined, resulting in the final guidance statements on the (1) evaluation of fracture risk; (2) stratification of risk priorities; (3) indications of bone density scans and lab tests; (4) initiation and continuation of pharmacologic therapy; (5) interruptions of therapy; (6) treatment of patients with incident fracture; (7) physical therapy and fall prevention; and (8) nutritional interventions.

CONCLUSION: These guidance statements are provided to promote optimal care to patients at risk for osteoporosis and fracture, during the current COVID-19 pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a "living document" and future updates are anticipated.},
}

Aged
*COVID-19
Humans
*Medicine
*Orthopedics
*Osteoporosis/epidemiology/therapy
Pandemics
SARS-CoV-2
*Traumatology

@article {pmid33419600,
year = {2021},
author = {White, SJ and Barello, S and Cao di San Marco, E and Colombo, C and Eeckman, E and Gilligan, C and Graffigna, G and Jirasevijinda, T and Mosconi, P and Mullan, J and Rehman, SU and Rubinelli, S and Vegni, E and Krystallidou, D},
title = {Critical observations on and suggested ways forward for healthcare communication during COVID-19: pEACH position paper.},
journal = {Patient education and counseling},
volume = {104},
number = {2},
pages = {217-222},
pmid = {33419600},
issn = {1873-5134},
mesh = {*COVID-19 ; *Health Communication ; Health Literacy ; Health Personnel/*psychology ; Health Promotion/*methods ; Humans ; Pandemics ; *Public Health Practice ; *SARS-CoV-2 ; *Telemedicine ; Uncertainty ; },
abstract = {OBJECTIVE: Communication in healthcare has influenced and been influenced by the COVID-19 pandemic. In this position paper, we share observations based on the latest available evidence and experiential knowledge that have emerged during the pandemic, with a specific focus on policy and practice.

METHODS: This is a position paper that presents observations relating to policy and practice in communication in healthcare related to COVID-19.

RESULTS: Through our critical observations as experts in the field of healthcare communication, we share our stance how healthcare communication has occured during the pandemic and suggest possible ways of improving policy and professional practice. We make recommendations for policy makers, healthcare providers, and communication experts while also highlighting areas that merit further investigation regarding healthcare communication in times of healthcare crises.

CONCLUSION: We have witnessed an upheaval of healthcare practice and the development of policy on-the-run. To ensure that policy and practice are evidence-based, person-centred, more inclusive and equitable, we advocate for critical reflection on this symbiotic relationship between COVID-19 and the central role of communication in healthcare.

PRACTICE IMPLICATIONS: This paper provides a summary of the key areas for development in communication in healthcare during COVID-19. It offers recommendations for improvement and a call to review policies and practice to build resilience and inclusive and equitable responsiveness in communication in healthcare.},
}

*COVID-19
*Health Communication
Health Literacy
Health Personnel/*psychology
Health Promotion/*methods
Humans
Pandemics
*Public Health Practice
*SARS-CoV-2
*Telemedicine
Uncertainty

@article {pmid33416050,
year = {2021},
author = {Chieffo, A and Tarantini, G and Naber, CK and Barbato, E and Roffi, M and Stefanini, GG and Buchanan, GL and Buszman, P and Moreno, R and Zawiślak, B and Cayla, G and Danenberg, H and Da Silveira, JAB and Nef, H and James, SK and Mauri Ferre, J and Voskuil, M and Witt, N and Windecker, S and Baumbach, A and Dudek, D},
title = {Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI).},
journal = {EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
volume = {16},
number = {14},
pages = {1177-1186},
pmid = {33416050},
issn = {1969-6213},
mesh = {*COVID-19 ; *Cardiovascular Surgical Procedures ; *Elective Surgical Procedures ; Humans ; Masks ; *Pandemics ; Personal Protective Equipment ; SARS-CoV-2 ; },
abstract = {The rearrangement of healthcare services required to face the coronavirus disease 2019 (COVID-19) pandemic led to a drastic reduction in elective cardiac invasive procedures. We are already facing a "second wave" of infections and we might be dealing during the next months with a "third wave" and subsequently new waves. Therefore, during the different waves of the COVID-19 pandemic we have to face the problems of how to perform elective cardiac invasive procedures in non-COVID patients and which patients/procedures should be prioritised. In this context, the interplay between the pandemic stage, the availability of healthcare resources and the priority of specific cardiac disorders is crucial. Clear pathways for "hot" or presumed "hot" patients and "cold" patients are mandatory in each hospital. Depending on the local testing capacity and intensity of transmission in the area, healthcare facilities may test patients for SARS-CoV-2 infection before the interventional procedure, regardless of risk assessment for COVID-19. Pre-hospital testing should always be conducted in the presence of symptoms suggestive of SARS-CoV-2 infection. In cases of confirmed or suspected COVID-19 positive patients, full personal protective equipment using FFP 2/N95 masks, eye protection, gowning and gloves is indicated during cardiac interventions for healthcare workers. When patients have tested negative for COVID-19, medical masks may be sufficient. Indeed, individual patients should themselves wear medical masks during cardiac interventions and outpatient visits.},
}

*COVID-19
*Cardiovascular Surgical Procedures
*Elective Surgical Procedures
Humans
Masks
*Pandemics
Personal Protective Equipment
SARS-CoV-2

@article {pmid33378789,
year = {2021},
author = {Klimek, L and Jutel, M and Akdis, CA and Bousquet, J and Akdis, M and Torres, MJ and Agache, I and Canonica, GW and Del Giacco, S and O'Mahony, L and Shamji, MH and Schwarze, J and Untersmayr, E and Ring, J and Bedbrook, A and Worm, M and Zuberbier, T and Knol, E and Hoffmann-Sommergruber, K and Chivato, T},
title = {ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper.},
journal = {Allergy},
volume = {76},
number = {6},
pages = {1624-1628},
doi = {10.1111/all.14726},
pmid = {33378789},
issn = {1398-9995},
mesh = {BNT162 Vaccine ; *COVID-19 ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; *Vaccines/adverse effects ; },
abstract = {Further to the approval of the Coronavirus disease 2019 (COVID-19) vaccine BNT162b2, several severe anaphylaxis cases occured within the first few days of public vaccination. An investigation is taking place to understand the cases and their triggers. The vaccine will be administered to a large number of individuals worldwide and there are raising concerns that severe adverse events might occur. With the current information, the European Academy of Allergy and Clinical Immunology (EAACI) states its position for the following preliminary recommendations that are to be revised as soon as more data emerge. To minimize the risk of severe allergic reactions in vaccinated individuals, it is urgently required to understand the specific nature of the reported severe allergic reactions, including the background medical history of the individuals affected and the mechanisms involved. To achieve this goal, all clinical and laboratory information should be collected and reported. Mild and moderate allergic patients should not be excluded from the vaccine as this could have a significant impact on reaching the goal of population immunity. Healthcare practitioners vaccinating against COVID-19 are required to be sufficiently prepared to recognize and treat anaphylaxis properly with the ability to administer adrenaline. Further to vaccine administration, a mandatory observation period of at least 15 minutes should be followed for all individuals. The current data have not shown any higher risk for patients suffering from allergic rhinitis or asthma, and this message should be clearly stated by physicians to enable our patients to trust the vaccine. More than 30% of the population suffers from allergic diseases and the benefit of the vaccination clearly outweighs the risk of severe COVID-19 development.},
}

BNT162 Vaccine
*COVID-19
COVID-19 Vaccines
Humans
SARS-CoV-2
*Vaccines/adverse effects

@article {pmid33372938,
year = {2020},
author = {Corona, T and Castañón-González, JA and Clark-Peralta, P and García-Peña, C and Guevara-Guzmán, R and Domínguez-Cherit, G and Halabe-Cherem, J and López-Cervantes, M and Macias-Hernández, A and Rodríguez-Violante, M and Santillán-Doherty, P and Anda, GV and Guinzberg, AL},
title = {Position paper: Impact on medical and health personnel in the SARS-CoV-2 pandemic.},
journal = {Gaceta medica de Mexico},
volume = {156},
number = {5},
pages = {478-480},
doi = {10.24875/GMM.M20000432},
pmid = {33372938},
issn = {0016-3813},
mesh = {COVID-19/*prevention & control/*transmission ; *Health Personnel ; Humans ; Infectious Disease Transmission, Patient-to-Professional/*prevention & control ; Practice Guidelines as Topic ; },
}

COVID-19/*prevention & control/*transmission
*Health Personnel
Humans
Infectious Disease Transmission, Patient-to-Professional/*prevention & control
Practice Guidelines as Topic

@article {pmid33359375,
year = {2021},
author = {Mussini, C and Falcone, M and Nozza, S and Sagnelli, C and Parrella, R and Meschiari, M and Petrosillo, N and Mastroianni, C and Cascio, A and Iaria, C and Galli, M and Chirianni, A and Sagnelli, E and Iacobello, C and Di Perri, G and Mazzotta, F and Carosi, G and Tinelli, M and Grossi, P and Armignacco, O and Portelli, V and Andreoni, M and Tavio, M and , },
title = {Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT).},
journal = {Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
volume = {27},
number = {3},
pages = {389-395},
pmid = {33359375},
issn = {1469-0691},
mesh = {COVID-19/diagnosis/epidemiology/therapy ; Humans ; Italy/epidemiology ; *Practice Guidelines as Topic ; Randomized Controlled Trials as Topic ; SARS-CoV-2/isolation & purification ; Societies, Medical/*standards ; Standard of Care ; *COVID-19 Drug Treatment ; },
abstract = {SCOPE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting.

METHODS: The panel conducted a detailed review of the literature and eventual press releases from randomized clinical trials for each possible available treatment. Inductive PubMed search waws performed for publications relevant to the topic, including all clinical trials conducted. The result was a flowchart with treatment indications for patients with COVID-19.

IMPLICATIONS: After 6 months of a pandemic situation and before a possible second coronavirus wave descends on Europe, it is important to evaluate which drugs proved to be effective while also considering that results from many randomized clinical trials are still awaited. Indeed, among treatments for COVID-19, only glucocorticoids have resulted in an association with a significant decrease in mortality in published randomized controlled trials. New therapeutic strategies are urgently needed.},
}

COVID-19/diagnosis/epidemiology/therapy
Humans
Italy/epidemiology
*Practice Guidelines as Topic
Randomized Controlled Trials as Topic
SARS-CoV-2/isolation & purification
Societies, Medical/*standards
Standard of Care
*COVID-19 Drug Treatment

@article {pmid33313664,
year = {2021},
author = {Diller, GP and Gatzoulis, MA and Broberg, CS and Aboulhosn, J and Brida, M and Schwerzmann, M and Chessa, M and Kovacs, AH and Roos-Hesselink, J},
title = {Coronavirus disease 2019 in adults with congenital heart disease: a position paper from the ESC working group of adult congenital heart disease, and the International Society for Adult Congenital Heart Disease.},
journal = {European heart journal},
volume = {42},
number = {19},
pages = {1858-1865},
pmid = {33313664},
issn = {1522-9645},
mesh = {Adult ; *COVID-19 ; *Cardiovascular Diseases ; *Heart Defects, Congenital/complications/epidemiology/therapy ; Humans ; Pandemics ; SARS-CoV-2 ; },
abstract = {We are witnessing an unparalleled pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated with coronavirus disease 2019 (COVID-19). Current data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young patients affected. Nevertheless, the severity of COVID-19 respiratory syndrome and the risk of adverse or catastrophic outcomes are increased in patients with pre-existing cardiovascular disease. Patients with adult congenital heart disease (ACHD)-by definition-have underlying cardiovascular disease. Many patients with ACHD are also afflicted with residual haemodynamic lesions such as valve dysfunction, diminished ventricular function, arrhythmias or cyanosis, have extracardiac comorbidities, and face additional challenges regarding pregnancy. Currently, there are emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratification and treatment considerations, remain unclear. In this article, we aim to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology, risk stratification for work, self-isolation, hospitalization, impact on pregnancy, psychosocial health, and longer-term implications for the provision of ACHD care.},
}

Adult
*COVID-19
*Cardiovascular Diseases
*Heart Defects, Congenital/complications/epidemiology/therapy
Humans
Pandemics
SARS-CoV-2

@article {pmid33295471,
year = {2020},
author = {Marques-Santos, C and Avila, WS and Carvalho, RCM and Lucena, AJG and Freire, CMV and Alexandre, ERG and Campanharo, FF and Rivera, MAMR and Costa, MENC and Castro, ML},
title = {Position Statement on COVID-19 and Pregnancy in Women with Heart Disease Department of Women Cardiology of the Brazilian Society of Cardiology - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {115},
number = {5},
pages = {975-986},
pmid = {33295471},
issn = {1678-4170},
mesh = {Brazil ; *COVID-19 ; *Cardiology ; Female ; *Heart Diseases ; Humans ; Pandemics ; Practice Guidelines as Topic ; Pregnancy ; *Pregnancy Complications, Neoplastic ; SARS-CoV-2 ; Societies, Medical ; },
}

Brazil
*COVID-19
*Cardiology
Female
*Heart Diseases
Humans
Pandemics
Practice Guidelines as Topic
Pregnancy
*Pregnancy Complications, Neoplastic
SARS-CoV-2
Societies, Medical

@article {pmid33178656,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Yaya, S and Sunil, T and Thomas, P and Mucci, V and Moguilner, S and Israel-Korn, S and Alacapa, J and Mishra, A and Pandya, S and Schroeder, S and Atreja, A and Banach, M and Ray, D},
title = {Telemedicine Across the Globe-Position Paper From the COVID-19 Pandemic Health System Resilience PROGRAM (REPROGRAM) International Consortium (Part 1).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {556720},
pmid = {33178656},
issn = {2296-2565},
mesh = {*COVID-19 ; Humans ; Pandemics/prevention & control ; Public Health ; SARS-CoV-2 ; *Telemedicine ; },
abstract = {Coronavirus disease 2019 (COVID-19) has accelerated the adoption of telemedicine globally. The current consortium critically examines the telemedicine frameworks, identifies gaps in its implementation and investigates the changes in telemedicine framework/s during COVID-19 across the globe. Streamlining of global public health preparedness framework that is interoperable and allow for collaboration and sharing of resources, in which telemedicine is an integral part of the public health response during outbreaks such as COVID-19, should be pursued. With adequate reinforcement, telemedicine has the potential to act as the "safety-net" of our public health response to an outbreak. Our focus on telemedicine must shift to the developing and under-developing nations, which carry a disproportionate burden of vulnerable communities who are at risk due to COVID-19.},
}

*COVID-19
Humans
Pandemics/prevention & control
Public Health
SARS-CoV-2
*Telemedicine

@article {pmid33123943,
year = {2021},
author = {Defrancesco, M and Bancher, C and Dal-Bianco, P and Hinterhuber, H and Schmidt, R and Struhal, W and Ransmayr, G and Stögmann, E and Marksteiner, J},
title = {[Position paper of the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) : Effects of the COVID-19 pandemic in Austria on people with dementia and their care environment-problem areas, recommendations, and strategies].},
journal = {Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater},
volume = {35},
number = {1},
pages = {35-47},
pmid = {33123943},
issn = {2194-1327},
mesh = {Aged ; Aged, 80 and over ; *Alzheimer Disease/therapy ; Austria ; *COVID-19/epidemiology ; Communicable Disease Control ; *Dementia/therapy ; Humans ; *Pandemics ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {Older adults are particularly affected by the current COVID-19 (SARS-CoV-2) pandemic. The risk of dying from COVID-19 increases with age and is often associated with pre-existing health conditions. Globally, more than 50 million-in Austria currently approximately 140,000 people-suffer from dementia. The co-occurrence of dementia as a "pandemic of old age" together with the COVID-19 pandemic has a double impact on persons living with dementia and their caregivers. The COVID-19 pandemic poses major challenges for individuals with dementia and their caregivers: (1) People with dementia have limited access to information on COVID-19, may have difficulties with protective measures such as wearing masks and in remembering safety regulations. (2) People with dementia live alone or with their family, or are institutionalized. To reduce the chance of infection among older people in nursing homes, Austrian local authorities have banned visitors to nursing homes and long-term care facilities and implemented strict social-distancing measures. As a result, older people lost face-to-face contact with their family members, became isolated and social activities stopped. Consequently, anxiety, stress and serious concerns about infections among staff in nursing homes increased and they developed signs of exhaustion and burnout during the full lockdown of the facilities. Thus, due to the emerging COVID-19 crisis, the Austrian Alzheimer Association (Österreichische Alzheimer Gesellschaft, ÖAG) and international societies developed recommendations to support people living with dementia and their caregivers on various issues of physical and mental health.},
}

Aged
Aged, 80 and over
*Alzheimer Disease/therapy
Austria
*COVID-19/epidemiology
Communicable Disease Control
*Dementia/therapy
Humans
*Pandemics
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid33075144,
year = {2021},
author = {Klimek, L and Jutel, M and Bousquet, J and Agache, I and Akdis, CA and Hox, V and Gevaert, P and Tomazic, PV and Rondon, C and Cingi, C and Toppila-Salmi, S and Karavelia, A and Bozkurt, B and Förster-Ruhrmann, U and Becker, S and Chaker, AM and Wollenberg, B and Mösges, R and Huppertz, T and Hagemann, J and Bachert, C and Fokkens, W},
title = {Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper.},
journal = {Allergy},
volume = {76},
number = {3},
pages = {677-688},
doi = {10.1111/all.14629},
pmid = {33075144},
issn = {1398-9995},
mesh = {Adrenal Cortex Hormones/administration & dosage ; Asthma/drug therapy ; Biological Products/therapeutic use ; COVID-19/*epidemiology ; Chronic Disease ; Humans ; Nasal Polyps/drug therapy ; Rhinitis/*drug therapy ; *SARS-CoV-2 ; Sinusitis/*drug therapy ; },
abstract = {BACKGROUND: Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID-19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type-2 (T2) inflammation endotypes.

METHODS: The current knowledge on COVID-19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet.

RESULTS: Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID-19 pandemic.

CONCLUSION: Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS-CoV-2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID-19 infection.},
}

Adrenal Cortex Hormones/administration & dosage
Asthma/drug therapy
Biological Products/therapeutic use
COVID-19/*epidemiology
Chronic Disease
Humans
Nasal Polyps/drug therapy
Rhinitis/*drug therapy
*SARS-CoV-2
Sinusitis/*drug therapy

@article {pmid33027040,
year = {2020},
author = {Bossuyt, X and Damoiseaux, J and Rasmussen, N and van Paassen, P and Hellmich, B and Baslund, B and Blockmans, D and Vermeersch, P and Lopez-Hoyos, M and Vercammen, M and Barret, E and Hammar, F and Leinfelder, U and Mahler, M and Olschowka, N and Roggenbuck, D and Schlumberger, W and Walker, R and Rönnelid, J and Cohen Tervaert, JW and Csernok, E and Fierz, W and , },
title = {Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper.},
journal = {Clinical chemistry and laboratory medicine},
volume = {59},
number = {2},
pages = {e35-e39},
doi = {10.1515/cclm-2020-1178},
pmid = {33027040},
issn = {1437-4331},
mesh = {Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology ; Antibodies, Antineutrophil Cytoplasmic/*blood ; Calibration ; Data Interpretation, Statistical ; Diagnosis, Differential ; Humans ; Immunoassay/methods/*standards ; Likelihood Functions ; Myeloblastin/immunology ; Peroxidase/immunology ; Reference Standards ; Sensitivity and Specificity ; },
}

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood/*diagnosis/immunology
Antibodies, Antineutrophil Cytoplasmic/*blood
Calibration
Data Interpretation, Statistical
Diagnosis, Differential
Humans
Immunoassay/methods/*standards
Likelihood Functions
Myeloblastin/immunology
Peroxidase/immunology
Reference Standards
Sensitivity and Specificity

@article {pmid33014958,
year = {2020},
author = {Bhaskar, S and Bradley, S and Chattu, VK and Adisesh, A and Nurtazina, A and Kyrykbayeva, S and Sakhamuri, S and Moguilner, S and Pandya, S and Schroeder, S and Banach, M and Ray, D},
title = {Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2).},
journal = {Frontiers in public health},
volume = {8},
number = {},
pages = {410},
pmid = {33014958},
issn = {2296-2565},
mesh = {*Ambulatory Care Facilities ; COVID-19/*prevention & control ; Health Personnel ; Humans ; Pandemics ; Physical Distancing ; Telemedicine/*trends ; Videoconferencing ; },
abstract = {Technology has acted as a great enabler of patient continuity through remote consultation, ongoing monitoring, and patient education using telephone and videoconferencing in the coronavirus disease 2019 (COVID-19) era. The devastating impact of COVID-19 is bound to prevail beyond its current reign. The vulnerable sections of our community, including the elderly, those from lower socioeconomic backgrounds, those with multiple comorbidities, and immunocompromised patients, endure a relatively higher burden of a pandemic such as COVID-19. The rapid adoption of different technologies across countries, driven by the need to provide continued medical care in the era of social distancing, has catalyzed the penetration of telemedicine. Limiting the exposure of patients, healthcare workers, and systems is critical in controlling the viral spread. Telemedicine offers an opportunity to improve health systems delivery, access, and efficiency. This article critically examines the current telemedicine landscape and challenges in its adoption, toward remote/tele-delivery of care, across various medical specialties. The current consortium provides a roadmap and/or framework, along with recommendations, for telemedicine uptake and implementation in clinical practice during and beyond COVID-19.},
}

*Ambulatory Care Facilities
COVID-19/*prevention & control
Health Personnel
Humans
Pandemics
Physical Distancing
Telemedicine/*trends
Videoconferencing

@article {pmid32945570,
year = {2020},
author = {Bryant, PA and Rogers, BA and Cowan, R and Bowen, AC and Pollard, J and , },
title = {Planning and clinical role of acute medical home care services for COVID-19: consensus position statement by the Hospital-in-the-Home Society Australasia.},
journal = {Internal medicine journal},
volume = {50},
number = {10},
pages = {1267-1271},
pmid = {32945570},
issn = {1445-5994},
mesh = {Australasia/epidemiology ; Betacoronavirus ; COVID-19 ; Communication ; Coronavirus Infections/*epidemiology/*therapy ; Equipment and Supplies, Hospital/supply & distribution ; Health Workforce/organization & administration ; Home Care Services/*organization & administration ; Humans ; Infection Control/organization & administration ; Occupational Exposure/prevention & control ; Pandemics ; Patient-Centered Care/organization & administration ; Pneumonia, Viral/*epidemiology/*therapy ; SARS-CoV-2 ; Workload ; },
abstract = {During a pandemic when hospitals are stretched and patients need isolation, the role of hospital-in-the-home (HITH) providing acute medical care at home has never been more relevant. We aimed to define and address the challenges to acute home care services posed by the COVID-19 pandemic. Planning for service operation involves staffing, equipment availability and cleaning, upskilling in telehealth and communication. Planning for clinical care involves maximising cohorts of patients without COVID-19 and new clinical pathways for patients with COVID-19. The risk of SARS-CoV-2 transmission, specific COVID-19 clinical pathways and the well-being of patients and staff should be addressed in advance.},
}

Australasia/epidemiology
Betacoronavirus
COVID-19
Communication
Coronavirus Infections/*epidemiology/*therapy
Equipment and Supplies, Hospital/supply & distribution
Health Workforce/organization & administration
Home Care Services/*organization & administration
Humans
Infection Control/organization & administration
Occupational Exposure/prevention & control
Pandemics
Patient-Centered Care/organization & administration
Pneumonia, Viral/*epidemiology/*therapy
SARS-CoV-2
Workload

@article {pmid32941344,
year = {2020},
author = {Oliva, A and Caputo, M and Grassi, S and Vetrugno, G and Marazza, M and Ponzanelli, G and Cauda, R and Scambia, G and Forti, G and Bellantone, R and Pascali, VL},
title = {Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement.},
journal = {Journal of patient safety},
volume = {16},
number = {4},
pages = {e299-e302},
pmid = {32941344},
issn = {1549-8425},
mesh = {Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/epidemiology ; Health Personnel/*legislation & jurisprudence ; Humans ; Italy/epidemiology ; *Legislation, Hospital ; *Liability, Legal ; Pandemics/*legislation & jurisprudence ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; },
abstract = {BACKGROUND: On May 12, 2020, a symposium titled "Liability of healthcare professionals and institutions during COVID-19 pandemic" was held in Italy with the participation of national experts in malpractice law, hospital management, legal medicine, and clinical risk management. The symposium's rationale was the highly likely inflation of criminal and civil proceedings concerning alleged errors committed by health care professionals and decision makers during the COVID-19 pandemic. Its aim was to identify and discuss the main issues of legal and medicolegal interest and thus to find solid solutions in the spirit of preparedness planning.

METHODS: There were 5 main points of discussion: (A) how to judge errors committed during the pandemic because of the application of protocols and therapies based on no or weak evidence of efficacy, (B) whether hospital managers can be considered liable for infected health care professionals who were not given adequate personal protective equipment, (C) whether health care professionals and institutions can be considered liable for cases of infected inpatients who claim that the infection was transmitted in a hospital setting, (D) whether health care institutions and hospital managers can be considered liable for the hotspots in long-term care facilities/care homes, and (E) whether health care institutions and hospital managers can be considered liable for the worsening of chronic diseases.

RESULTS AND CONCLUSION: Limitation of the liability to the cases of gross negligence (with an explicit definition of this term), a no-fault system with statal indemnities for infected cases, and a rigorous methodology for the expert witnesses were proposed as key interventions for successfully facing future proceedings.},
}

Betacoronavirus/isolation & purification
COVID-19
Coronavirus Infections/epidemiology
Health Personnel/*legislation & jurisprudence
Humans
Italy/epidemiology
*Legislation, Hospital
*Liability, Legal
Pandemics/*legislation & jurisprudence
Pneumonia, Viral/epidemiology
SARS-CoV-2

@article {pmid32933562,
year = {2020},
author = {Villani, A and Bozzola, E and Staiano, A and Agostiniani, R and Del Vecchio, A and Zamperini, N and Marino, F and Vecchio, D and Corsello, G},
title = {Facial masks in children: the position statement of the Italian pediatric society.},
journal = {Italian journal of pediatrics},
volume = {46},
number = {1},
pages = {132},
pmid = {32933562},
issn = {1824-7288},
mesh = {*Betacoronavirus ; COVID-19 ; Child ; *Consensus ; Coronavirus Infections/epidemiology/*transmission ; Disease Transmission, Infectious/*prevention & control ; Equipment Design ; Humans ; Infection Control/*organization & administration ; Masks/standards/*supply & distribution ; Pandemics ; Pneumonia, Viral/epidemiology/*transmission ; SARS-CoV-2 ; },
abstract = {Facial masks may be one of the most cost-effective strategies to prevent the diffusion of COVID 19 infection. Nevertheless, fake news are spreading, alerting parents on dangerous side effects in children, such as hypercapnia, hypoxia, gut dysbiosis and immune system weakness. Aim of the Italian Pediatric Society statement is to face misconception towards the use of face masks and to spread scientific trustable information.},
}

*Betacoronavirus
COVID-19
Child
*Consensus
Coronavirus Infections/epidemiology/*transmission
Disease Transmission, Infectious/*prevention & control
Equipment Design
Humans
Infection Control/*organization & administration
Masks/standards/*supply & distribution
Pandemics
Pneumonia, Viral/epidemiology/*transmission
SARS-CoV-2

@article {pmid32890777,
year = {2020},
author = {Greenspan, H and San José Estépar, R and Niessen, WJ and Siegel, E and Nielsen, M},
title = {Position paper on COVID-19 imaging and AI: From the clinical needs and technological challenges to initial AI solutions at the lab and national level towards a new era for AI in healthcare.},
journal = {Medical image analysis},
volume = {66},
number = {},
pages = {101800},
pmid = {32890777},
issn = {1361-8423},
support = {R01 HL149877/HL/NHLBI NIH HHS/United States ; R21 HL140422/HL/NHLBI NIH HHS/United States ; },
mesh = {Algorithms ; Artificial Intelligence/*trends ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*diagnostic imaging ; Diagnostic Imaging/*methods ; Humans ; Pandemics ; Pneumonia, Viral/*diagnostic imaging ; SARS-CoV-2 ; },
abstract = {In this position paper, we provide a collection of views on the role of AI in the COVID-19 pandemic, from clinical requirements to the design of AI-based systems, to the translation of the developed tools to the clinic. We highlight key factors in designing system solutions - per specific task; as well as design issues in managing the disease at the national level. We focus on three specific use-cases for which AI systems can be built: early disease detection, management in a hospital setting, and building patient-specific predictive models that require the combination of imaging with additional clinical data. Infrastructure considerations and population modeling in two European countries will be described. This pandemic has made the practical and scientific challenges of making AI solutions very explicit. A discussion concludes this paper, with a list of challenges facing the community in the AI road ahead.},
}

Algorithms
Artificial Intelligence/*trends
Betacoronavirus
COVID-19
Coronavirus Infections/*diagnostic imaging
Diagnostic Imaging/*methods
Humans
Pandemics
Pneumonia, Viral/*diagnostic imaging
SARS-CoV-2

@article {pmid32882035,
year = {2020},
author = {Rutkowski, JL and Camm, DP and El Chaar, E},
title = {AAID White Paper: Management of the Dental Implant Patient During the COVID-19 Pandemic and Beyond.},
journal = {The Journal of oral implantology},
volume = {46},
number = {5},
pages = {454-466},
doi = {10.1563/aaid-joi-D-20-00316},
pmid = {32882035},
issn = {0160-6972},
mesh = {*Betacoronavirus ; *COVID-19 ; *Dental Implants ; Humans ; Pandemics ; United States ; },
abstract = {The scientific community's understanding of how the SARS-CoV-2 virus is transmitted and how to best mitigate its spread is improving daily. To help protect patients from acquiring COVID-19 from a dental office nosocomial infection, many state or local governments have classified dental treatments as "nonessential" and have paused routine dental care. Dentists have been instructed to perform only procedures designated as emergencies. Unfortunately, there is not a good understanding of what a dental emergency is among governmental leaders. What a government agency may perceive as an elective procedure may be seen as "essential" by the dental clinician responsible for maintaining the oral health of the patient. Each dental specialty understands the effects delayed care has on a patient's oral and systemic health. Dentistry has made extensive progress in improving oral health through prevention of the dental emergency. The dental profession must work together to prevent the reversal of the progress dentistry and patients have made. This American Academy of Implant Dentistry (AAID) White Paper discusses what COVID-19 is and how it impacts dental treatments, presents guidelines for dentistry in general and for dental implant related treatments, specifically. Recommendations for implant dentistry include the following: (1) what constitutes a dental implant related emergency, (2) how patients should be screened and triaged, (3) what personal protective equipment is necessary, (4) how operatories should be equipped, (5) what equipment should be used, and (6) what, when, and how procedures can be performed. This paper is intended to provide guidance for the dental implant practice so patients and dental health care providers can be safe, and offices can remain open and viable during the pandemic.},
}

*Betacoronavirus
*COVID-19
*Dental Implants
Humans
Pandemics
United States

@article {pmid32876200,
year = {2020},
author = {Soeiro, AM and Leal, TCAT and Pereira, MP and Lima, EG and Figueiredo, ACBDS and Petriz, JLF and Precoma, DB and Serrano, CV},
title = {Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {115},
number = {2},
pages = {292-301},
pmid = {32876200},
issn = {1678-4170},
mesh = {Anticoagulants/*therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Pandemics ; Platelet Aggregation Inhibitors/*therapeutic use ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; },
}

Anticoagulants/*therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections/*drug therapy
Humans
Pandemics
Platelet Aggregation Inhibitors/*therapeutic use
Pneumonia, Viral/*drug therapy
SARS-CoV-2

@article {pmid32871013,
year = {2020},
author = {Noel, JM and Jackson, CW},
title = {ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder.},
journal = {American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
volume = {77},
number = {24},
pages = {2114-2132},
doi = {10.1093/ajhp/zxaa303},
pmid = {32871013},
issn = {1535-2900},
mesh = {Adult ; Antipsychotic Agents/*administration & dosage/adverse effects ; Humans ; Psychotic Disorders/*drug therapy ; Schizophrenia/*drug therapy ; Societies, Pharmaceutical ; United States ; },
abstract = {In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.},
}

Adult
Antipsychotic Agents/*administration & dosage/adverse effects
Humans
Psychotic Disorders/*drug therapy
Schizophrenia/*drug therapy
Societies, Pharmaceutical
United States

@article {pmid32825892,
year = {2020},
author = {Vora, A and Arora, VK and Behera, D and Tripathy, SK},
title = {White paper on Ivermectin as a potential therapy for COVID-19.},
journal = {The Indian journal of tuberculosis},
volume = {67},
number = {3},
pages = {448-451},
pmid = {32825892},
issn = {0019-5707},
mesh = {Antiparasitic Agents/therapeutic use ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Ivermectin/*therapeutic use ; Pandemics ; Pneumonia, Viral/*drug therapy ; Risk Factors ; SARS-CoV-2 ; Treatment Outcome ; },
abstract = {A group of senior doctors with vast clinical experience met on 19th July'20 under the aegis of Academy of Advanced Medical Education. The panel looked at Ivermectin, one of the old molecule and evaluated it's use in COVID 19 (Novel Coronavirus Disease 2019) management. After critical panel discussion, all the attending doctors came to a conclusion that Ivermectin can be a potential molecule for prophylaxis and treatment of people infected with Coronavirus, owing to its anti-viral properties coupled with effective cost, availability and good tolerability and safety.},
}

Antiparasitic Agents/therapeutic use
*Betacoronavirus
COVID-19
Coronavirus Infections/*drug therapy
Humans
Ivermectin/*therapeutic use
Pandemics
Pneumonia, Viral/*drug therapy
Risk Factors
SARS-CoV-2
Treatment Outcome

@article {pmid32823368,
year = {2020},
author = {Pfaar, O and Klimek, L and Worm, M and Bergmann, KC and Bieber, T and Buhl, R and Buters, J and Darsow, U and Keil, T and Kleine-Tebbe, J and Lau, S and Maurer, M and Merk, H and Mösges, R and Saloga, J and Staubach, P and Stute, P and Rabe, K and Rabe, U and Vogelmeier, C and Biedermann, T and Jung, K and Schlenter, W and Ring, J and Chaker, A and Wehrmann, W and Becker, S and Mülleneisen, N and Nemat, K and Czech, W and Wrede, H and Brehler, R and Fuchs, T and Tomazic, PV and Aberer, W and Fink-Wagner, A and Horak, F and Wöhrl, S and Niederberger-Leppin, V and Pali-Schöll, I and Pohl, W and Roller-Wirnsberger, R and Spranger, O and Valenta, R and Akdis, M and Akdis, C and Hoffmann-Sommergruber, K and Jutel, M and Matricardi, P and Spertini, F and Khaltaev, N and Michel, JP and Nicod, L and Schmid-Grendelmeier, P and Hamelmann, E and Jakob, T and Werfel, T and Wagenmann, M and Taube, C and Gerstlauer, M and Vogelberg, C and Bousquet, J and Zuberbier, T},
title = {[Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI-AeDA-GPA-DGAKI Position Paper (Pocket-Guide)].},
journal = {Laryngo- rhino- otologie},
volume = {99},
number = {10},
pages = {676-679},
doi = {10.1055/a-1170-8426},
pmid = {32823368},
issn = {1438-8685},
mesh = {*Betacoronavirus ; COVID-19 ; *Coronavirus Infections ; Desensitization, Immunologic ; Humans ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; },
}

*Betacoronavirus
COVID-19
*Coronavirus Infections
Desensitization, Immunologic
Humans
*Pandemics
*Pneumonia, Viral
SARS-CoV-2

@article {pmid32754159,
year = {2020},
author = {Bhaskar, S and Sinha, A and Banach, M and Mittoo, S and Weissert, R and Kass, JS and Rajagopal, S and Pai, AR and Kutty, S},
title = {Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.},
journal = {Frontiers in immunology},
volume = {11},
number = {},
pages = {1648},
pmid = {32754159},
issn = {1664-3224},
support = {001/WHO_/World Health Organization/International ; },
mesh = {Adrenal Cortex Hormones/therapeutic use ; Angiotensin-Converting Enzyme 2 ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Betacoronavirus/*immunology ; CD4-CD8 Ratio ; CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; COVID-19 ; Clinical Decision-Making/methods ; Coronavirus Infections/blood/*drug therapy/*immunology/mortality ; Critical Care/*methods ; Critical Illness ; Cytokines/*blood ; Endothelial Cells/metabolism ; Female ; Humans ; Immunocompromised Host ; Interleukin-6/antagonists & inhibitors ; Janus Kinase Inhibitors/therapeutic use ; Male ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Pneumonia, Viral/blood/*drug therapy/*immunology/mortality ; SARS-CoV-2 ; Sex Factors ; Thrombosis ; },
abstract = {Cytokine storm is an acute hyperinflammatory response that may be responsible for critical illness in many conditions including viral infections, cancer, sepsis, and multi-organ failure. The phenomenon has been implicated in critically ill patients infected with SARS-CoV-2, the novel coronavirus implicated in COVID-19. Critically ill COVID-19 patients experiencing cytokine storm are believed to have a worse prognosis and increased fatality rate. In SARS-CoV-2 infected patients, cytokine storm appears important to the pathogenesis of several severe manifestations of COVID-19: acute respiratory distress syndrome, thromboembolic diseases such as acute ischemic strokes caused by large vessel occlusion and myocardial infarction, encephalitis, acute kidney injury, and vasculitis (Kawasaki-like syndrome in children and renal vasculitis in adult). Understanding the pathogenesis of cytokine storm will help unravel not only risk factors for the condition but also therapeutic strategies to modulate the immune response and deliver improved outcomes in COVID-19 patients at high risk for severe disease. In this article, we present an overview of the cytokine storm and its implications in COVID-19 settings and identify potential pathways or biomarkers that could be targeted for therapy. Leveraging expert opinion, emerging evidence, and a case-based approach, this position paper provides critical insights on cytokine storm from both a prognostic and therapeutic standpoint.},
}

Adrenal Cortex Hormones/therapeutic use
Angiotensin-Converting Enzyme 2
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Betacoronavirus/*immunology
CD4-CD8 Ratio
CD4-Positive T-Lymphocytes/immunology
CD8-Positive T-Lymphocytes/immunology
COVID-19
Clinical Decision-Making/methods
Coronavirus Infections/blood/*drug therapy/*immunology/mortality
Critical Care/*methods
Critical Illness
Cytokines/*blood
Endothelial Cells/metabolism
Female
Humans
Immunocompromised Host
Interleukin-6/antagonists & inhibitors
Janus Kinase Inhibitors/therapeutic use
Male
Pandemics
Peptidyl-Dipeptidase A/metabolism
Pneumonia, Viral/blood/*drug therapy/*immunology/mortality
SARS-CoV-2
Sex Factors
Thrombosis

@article {pmid32748068,
year = {2020},
author = {Stolbach, A and Mazer-Amirshahi, M and Schwarz, ES and Juurlink, D and Wiegand, TJ and Nelson, LS},
title = {ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {4},
pages = {484-486},
pmid = {32748068},
issn = {1937-6995},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology ; Health Services Accessibility ; Humans ; Opioid-Related Disorders/*therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; Toxicology ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology
Health Services Accessibility
Humans
Opioid-Related Disorders/*therapy
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2
Toxicology

@article {pmid32740024,
year = {2020},
author = {Maculotti, D and Spena, PR and Villa, G},
title = {POSITION STATEMENT ON CARE OF OSTOMY PATIENTS DURING COVID-19 PANDEMIC.},
journal = {Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates},
volume = {43},
number = {4},
pages = {324-326},
doi = {10.1097/SGA.0000000000000539},
pmid = {32740024},
issn = {1538-9766},
mesh = {Ambulatory Care ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology/prevention & control/transmission ; Hospitalization ; Humans ; Infection Control/*organization & administration ; *Ostomy ; Pandemics/prevention & control ; Patient Selection ; Pneumonia, Viral/*epidemiology/prevention & control/transmission ; SARS-CoV-2 ; },
}

Ambulatory Care
*Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology/prevention & control/transmission
Hospitalization
Humans
Infection Control/*organization & administration
*Ostomy
Pandemics/prevention & control
Patient Selection
Pneumonia, Viral/*epidemiology/prevention & control/transmission
SARS-CoV-2

@article {pmid32732509,
year = {2020},
author = {Moore, TA},
title = {Overview of the Care of Mothers and Newborns With COVID-19; Joint Position Statement.},
journal = {Advances in neonatal care : official journal of the National Association of Neonatal Nurses},
volume = {20},
number = {4},
pages = {268},
pmid = {32732509},
issn = {1536-0911},
mesh = {American Nurses' Association ; Betacoronavirus ; COVID-19 ; *Coronavirus Infections/epidemiology/prevention & control ; *Evidence-Based Nursing/methods/trends ; Female ; Humans ; Infant, Newborn ; Infection Control/organization & administration ; *Neonatal Nursing/organization & administration/standards ; Organizational Innovation ; *Pandemics/prevention & control ; *Pneumonia, Viral/epidemiology/prevention & control ; *Postnatal Care/methods/organization & administration/trends ; SARS-CoV-2 ; United States ; },
}

American Nurses' Association
Betacoronavirus
COVID-19
*Coronavirus Infections/epidemiology/prevention & control
*Evidence-Based Nursing/methods/trends
Female
Humans
Infant, Newborn
Infection Control/organization & administration
*Neonatal Nursing/organization & administration/standards
Organizational Innovation
*Pandemics/prevention & control
*Pneumonia, Viral/epidemiology/prevention & control
*Postnatal Care/methods/organization & administration/trends
SARS-CoV-2
United States

@article {pmid32719884,
year = {2020},
author = {Gutenbrunner, C and Stokes, EK and Dreinhöfer, K and Monsbakken, J and Clarke, S and Côté, P and Urseau, I and Constantine, D and Tardif, C and Balakrishna, V and Nugraha, B},
title = {Why Rehabilitation must have priority during and after the COVID-19-pandemic: A position statement of the Global Rehabilitation Alliance.},
journal = {Journal of rehabilitation medicine},
volume = {52},
number = {7},
pages = {jrm00081},
doi = {10.2340/16501977-2713},
pmid = {32719884},
issn = {1651-2081},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/prevention & control/*rehabilitation ; Global Health ; Health Services Accessibility/standards ; Humans ; Infection Control/standards ; Pandemics/prevention & control ; Pneumonia, Viral/prevention & control/*rehabilitation ; SARS-CoV-2 ; },
abstract = {COVID-19 has become a pandemic with strong influence on health systems. In many cases it leads to a disruption of rehabilitation service provision. On the other hand, rehabilitation must be an integral part of COVID-19 management. Rehabilitation for COVID-19 should start from acute and early post-acute care and needs to be continued in the post-acute and long-term rehabilitation phase. Of course, it should follow specific safety protocol. Additionally, rehabilitation must be kept available for all other people who are in need. From the perspective of health system, the Global Rehabilitation Alliance urges decision makers to ensure that rehabilitation services will be available for all patients with COVID-19 in the acute, post-acute and long-term phase. Additionally, it must be ensured that all other persons with rehabilitation need have access to rehabilitation services. Rehabilitation services must be equipped with personal protection equipment and follow strict hygiene measures. In particular, rehabilitation must be accessible for vulnerable populations. For that reason, rehabilitation must be kept a health priority during the COVID-19 pandemic and given adequate financial resources. Last but not least, scientific studies should be performed to clarify the impact of the pandemic on rehabilitation services as well as on the needs for rehabilitation of COVID-19 patients.},
}

*Betacoronavirus
COVID-19
Coronavirus Infections/prevention & control/*rehabilitation
Global Health
Health Services Accessibility/standards
Humans
Infection Control/standards
Pandemics/prevention & control
Pneumonia, Viral/prevention & control/*rehabilitation
SARS-CoV-2

@article {pmid32694078,
year = {2020},
author = {Vivas, D and Roldán, V and Esteve-Pastor, MA and Roldán, I and Tello-Montoliu, A and Ruiz-Nodar, JM and Cosín-Sales, J and Gámez, JM and Consuegra, L and Ferreiro, JL and Marín, F and , },
title = {Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology.},
journal = {Revista espanola de cardiologia (English ed.)},
volume = {73},
number = {9},
pages = {749-757},
pmid = {32694078},
issn = {1885-5857},
mesh = {*Betacoronavirus ; COVID-19 ; Cardiology ; Coronavirus Infections/*drug therapy ; Fibrinolytic Agents/*therapeutic use ; Humans ; Pandemics ; Patient Selection ; Pneumonia, Viral/*drug therapy ; SARS-CoV-2 ; Societies, Medical ; Spain ; COVID-19 Drug Treatment ; },
abstract = {The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy.},
}

*Betacoronavirus
COVID-19
Cardiology
Coronavirus Infections/*drug therapy
Fibrinolytic Agents/*therapeutic use
Humans
Pandemics
Patient Selection
Pneumonia, Viral/*drug therapy
SARS-CoV-2
Societies, Medical
Spain
COVID-19 Drug Treatment

@article {pmid32675009,
year = {2020},
author = {Torlone, E and Festa, C and Formoso, G and Scavini, M and Sculli, MA and Succurro, E and Sciacca, L and Di Bartolo, P and Purrello, F and Lapolla, A},
title = {Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian Diabetes Society (SID), diabetes, and pregnancy study group.},
journal = {Nutrition, metabolism, and cardiovascular diseases : NMCD},
volume = {30},
number = {9},
pages = {1418-1422},
pmid = {32675009},
issn = {1590-3729},
mesh = {*Betacoronavirus ; Blood Glucose/analysis ; COVID-19 ; Coronavirus Infections/*epidemiology ; Diabetes, Gestational/*diagnosis ; Female ; Glucose Tolerance Test ; Humans ; Italy ; Pandemics ; Pneumonia, Viral/*epidemiology ; Pregnancy ; SARS-CoV-2 ; },
abstract = {AIM: In response to the COVID-19 pandemic, there is a need for substantial changes in the procedures for accessing healthcare services. Even in the current pandemic, we should not reduce our attention towards the diagnosis and treatment of GDM. The purpose of this document is to provide a temporary guide for GDM screening, replacing the current guidelines when it is not possible to implement standard GDM screening because of an unfavorable risk/benefit ratio for pregnant women or when usual laboratory facilities are not available.

DATA SYNTHESIS: At the first visit during pregnancy, we must exclude the presence of "Overt diabetes" in all women. The criteria for the diagnosis of overt diabetes are either fasting plasma glucose ≥126 mg/dL, or random plasma glucose ≥200 mg/dL, or glycated hemoglobin ≥6.5%. When the screening procedure (OGTT) cannot be safely performed, the diagnosis of GDM is acceptable if fasting plasma glucose is ≥ 92 mg/dL. In order to consider the impaired fasting glucose as an acceptable surrogate for the diagnosis of GDM, the fasting glucose measurement should be performed within the recommended time windows for the risk level (high or medium risk).

CONCLUSIONS: The changes to the screening procedure for GDM reported below are specifically produced in response to the health emergency of the COVID-19 pandemic. Therefore, these recommended changes should cease to be in effect and should be replaced by current national guidelines when the healthcare authorities declare the end of this emergency.},
}

*Betacoronavirus
Blood Glucose/analysis
COVID-19
Coronavirus Infections/*epidemiology
Diabetes, Gestational/*diagnosis
Female
Glucose Tolerance Test
Humans
Italy
Pandemics
Pneumonia, Viral/*epidemiology
Pregnancy
SARS-CoV-2

@article {pmid32674177,
year = {2020},
author = {Kolditz, M and Dellweg, D and Geerdes-Fenge, H and Lepper, PM and Schaberg, T and Ewig, S and Pfeifer, M and Bauer, T},
title = {[Treatment with Dexamethasone in Patients with COVID-19 - A Position Paper of the German Respiratory Society (DGP)].},
journal = {Pneumologie (Stuttgart, Germany)},
volume = {74},
number = {8},
pages = {493-495},
pmid = {32674177},
issn = {1438-8790},
mesh = {Anti-Inflammatory Agents/*therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus/*isolation & purification ; Coronavirus Infections/diagnosis/*drug therapy ; Dexamethasone/*therapeutic use ; Germany ; Humans ; *Pandemics ; Pneumonia, Viral/diagnosis/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; Treatment Outcome ; COVID-19 Drug Treatment ; },
}

Anti-Inflammatory Agents/*therapeutic use
Betacoronavirus
COVID-19
Coronavirus/*isolation & purification
Coronavirus Infections/diagnosis/*drug therapy
Dexamethasone/*therapeutic use
Germany
Humans
*Pandemics
Pneumonia, Viral/diagnosis/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical
Treatment Outcome
COVID-19 Drug Treatment

@article {pmid32643767,
year = {2020},
author = {Gralnek, IM and Hassan, C and Beilenhoff, U and Antonelli, G and Ebigbo, A and Pellisé, M and Arvanitakis, M and Bhandari, P and Bisschops, R and Van Hooft, JE and Kaminski, MF and Triantafyllou, K and Webster, G and Voiosu, AM and Pohl, H and Dunkley, I and Fehrke, B and Gazic, M and Gjergek, T and Maasen, S and Waagenes, W and de Pater, M and Ponchon, T and Siersema, PD and Messmann, H and Dinis-Ribeiro, M},
title = {ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: An update on guidance during the post-lockdown phase and selected results from a membership survey.},
journal = {Endoscopy},
volume = {52},
number = {10},
pages = {891-898},
pmid = {32643767},
issn = {1438-8812},
mesh = {Humans ; Betacoronavirus ; *Coronavirus Infections ; COVID-19 ; *Endoscopy, Gastrointestinal ; *Pandemics ; *Pneumonia, Viral ; SARS-CoV-2 ; Surveys and Questionnaires ; },
}

Humans
Betacoronavirus
*Coronavirus Infections
COVID-19
*Endoscopy, Gastrointestinal
*Pandemics
*Pneumonia, Viral
SARS-CoV-2
Surveys and Questionnaires

@article {pmid32638902,
year = {2020},
author = {Guimarães, HP and Timerman, S and Rodrigues, RDR and Corrêa, TD and Schubert, DUC and Freitas, AP and Rea Neto, Á and Polastri, TF and Vane, MF and Couto, TB and Brandão, ACA and Giannetti, NS and Timerman, T and Hajjar, LA and Bacal, F and Lopes, MACQ},
title = {Position Statement: Cardiopulmonary Resuscitation of Patients with Confirmed or Suspected COVID-19 - 2020.},
journal = {Arquivos brasileiros de cardiologia},
volume = {114},
number = {6},
pages = {1078-1087},
pmid = {32638902},
issn = {1678-4170},
mesh = {Advisory Committees ; Betacoronavirus ; Brazil/epidemiology ; COVID-19 ; Cardiopulmonary Resuscitation/methods/*standards ; *Coronavirus ; Coronavirus Infections/diagnosis/epidemiology/*therapy ; Humans ; *Pandemics ; Pneumonia, Viral/diagnosis/epidemiology/*therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; United States ; },
abstract = {Care for patients with cardiac arrest in the context of the coronavirus disease 2019 (COVID-19) pandemic has several unique aspects that warrant particular attention. This joint position statement by the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Society of Cardiology (SBC), Brazilian Association of Intensive Care Medicine (AMIB), and Brazilian Society of Anesthesiology (SBA), all official societies representing the corresponding medical specialties affiliated with the Brazilian Medical Association (AMB), provides recommendations to guide health care workers in the current context of limited robust evidence, aiming to maximize the protection of staff and patients alike. It is essential that full aerosol precautions, which include wearing appropriate personal protective equipment, be followed during resuscitation. It is also imperative that potential causes of cardiac arrest of particular interest in this patient population, especially hypoxia, cardiac arrhythmias associated with QT prolongation, and myocarditis, be considered and addressed. An advanced invasive airway device should be placed early. Use of HEPA filters at the bag-valve interface is mandatory. Management of cardiac arrest occurring during mechanical ventilation or during prone positioning demands particular ventilator settings and rescuer positioning for chest compressions which deviate from standard cardiopulmonary resuscitation techniques. Apart from these logistical issues, care should otherwise follow national and international protocols and guidelines, namely the 2015 International Liaison Committee on Resuscitation (ILCOR) and 2019 American Heart Association (AHA) guidelines and the 2019 Update to the Brazilian Society of Cardiology Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Guideline.},
}

Advisory Committees
Betacoronavirus
Brazil/epidemiology
COVID-19
Cardiopulmonary Resuscitation/methods/*standards
*Coronavirus
Coronavirus Infections/diagnosis/epidemiology/*therapy
Humans
*Pandemics
Pneumonia, Viral/diagnosis/epidemiology/*therapy
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical
United States

@article {pmid32623686,
year = {2020},
author = {Stier, C and Lopez-Nava, G and Neto, MG and Thompson, CC and Campos, J and Khoursheed, M and Lakdawala, M and Ramos, A and Abu Dayyeh, BK},
title = {IFSO Endoscopy Committee Position Statement on the Practice of Bariatric Endoscopy During the COVID-19 Pandemic.},
journal = {Obesity surgery},
volume = {30},
number = {11},
pages = {4179-4186},
pmid = {32623686},
issn = {1708-0428},
mesh = {*Bariatrics ; *Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology/*prevention & control/transmission ; *Endoscopy ; Humans ; Infection Control/*organization & administration ; Obesity, Morbid/*surgery ; Pandemics/*prevention & control ; Patient Selection ; Pneumonia, Viral/epidemiology/*prevention & control/transmission ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {COVID-19 (Coronavirus disease 2019) caused by SARS-CoV-2 has become a global pandemic. Obesity is a risk factor for severe disease, and the practice of endoscopy poses special challenges and risks of SARS-CoV-2 transmission to patients and providers given the evolving role of the gastrointestinal tract in viral transmission and aerosol generation during endoscopic procedures. It is therefore necessary to distinguish between urgent interventions that cannot be postponed despite the risks during the pandemic and, in contrast, purely elective interventions that could be deferred in order to minimize transmission risks during a time of infection surge and limited access. Semi-urgent bariatric procedures have an intermediate position. Since the chronological course of the pandemic is still unpredictable, these interventions were defined according to whether or not they should be performed within a nominal 8-week period. In this position statement, the IFSO Endoscopy Committee offers guidance on navigating bariatric endoscopic procedures in patients with obesity during the COVID-19 pandemic, in the hope of mitigating the risk of SARS-CoV-2 transmission to vulnerable patients and healthcare workers. These recommendations may evolve as the pandemic progresses.},
}

*Bariatrics
*Betacoronavirus
COVID-19
Coronavirus Infections/epidemiology/*prevention & control/transmission
*Endoscopy
Humans
Infection Control/*organization & administration
Obesity, Morbid/*surgery
Pandemics/*prevention & control
Patient Selection
Pneumonia, Viral/epidemiology/*prevention & control/transmission
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32620315,
year = {2020},
author = {Miranda-Zazueta, G and González-Regueiro, JA and García-Juárez, I and Moctezuma-Velázquez, C and López-Díaz, FJ and Pérez-González, B and Uscanga-Domínguez, LF and Peláez-Luna, M},
title = {Pharmacologic management of patients with hepatic and pancreatic diseases that involve immunosuppressive therapies. Position statement within the framework of the SARS-CoV-2 (COVID-19) pandemic.},
journal = {Revista de gastroenterologia de Mexico (English)},
volume = {85},
number = {3},
pages = {312-320},
pmid = {32620315},
issn = {2255-534X},
mesh = {COVID-19 ; Coronavirus Infections/*complications ; Humans ; Immunosuppressive Agents/*adverse effects/*therapeutic use ; Liver Diseases/complications/*drug therapy ; Liver Transplantation ; Pancreas Transplantation ; Pancreatic Diseases/complications/*drug therapy ; *Pandemics ; Pneumonia, Viral/*complications ; },
abstract = {The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) virus. COVID-19 affected more than 6million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.},
}

COVID-19
Coronavirus Infections/*complications
Humans
Immunosuppressive Agents/*adverse effects/*therapeutic use
Liver Diseases/complications/*drug therapy
Liver Transplantation
Pancreas Transplantation
Pancreatic Diseases/complications/*drug therapy
*Pandemics
Pneumonia, Viral/*complications

@article {pmid32617893,
year = {2020},
author = {Farmer, BM and Cole, JB and Olives, TD and Farrell, NM and Rao, R and Nelson, LS and Mazer-Amirshahi, M and Stolbach, AI},
title = {ACMT Position Statement: Medication Administration and Safety During the Response to COVID-19 Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {4},
pages = {481-483},
pmid = {32617893},
issn = {1937-6995},
mesh = {*Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy/*epidemiology/prevention & control ; Health Personnel/education ; Humans ; Pandemics/prevention & control ; Personal Protective Equipment ; Pneumonia, Viral/drug therapy/*epidemiology/prevention & control ; SARS-CoV-2 ; Toxicology ; },
}

*Betacoronavirus
COVID-19
Coronavirus Infections/drug therapy/*epidemiology/prevention & control
Health Personnel/education
Humans
Pandemics/prevention & control
Personal Protective Equipment
Pneumonia, Viral/drug therapy/*epidemiology/prevention & control
SARS-CoV-2
Toxicology

@article {pmid32613918,
year = {2020},
author = {Geneid, A and Nawka, T and Schindler, A and Oguz, H and Chrobok, V and Calcinoni, O and Am Zehnhoff-Dinnesen, A and Neumann, K and Farahat, M and Abou-Elsaad, T and Moerman, M and Chavez, E and Fishman, J and Yazaki, R and Arnold, B and Frajkova, Z and Graf, S and Pflug, C and Drsata, J and Desuter, G and Samuelsson, C and Tedla, M and Costello, D and Sjögren, E and Hess, M and Kinnari, T and Rubin, J},
title = {Union of the European Phoniatricians' position statement on the exit strategy of phoniatric and laryngological services: staying safe and getting back to normal after the peak of coronavirus disease 2019 (issued on 25th May 2020).},
journal = {The Journal of laryngology and otology},
volume = {134},
number = {8},
pages = {661-664},
pmid = {32613918},
issn = {1748-5460},
mesh = {Audiology/*methods/standards ; Betacoronavirus/*isolation & purification ; COVID-19 ; Child ; Child, Preschool ; Coronavirus Infections/epidemiology/*prevention & control/virology ; Deglutition Disorders/diagnosis/surgery/virology ; Europe/epidemiology ; Humans ; Mandatory Testing/standards ; Otolaryngology/*methods/standards ; Pandemics/*prevention & control ; Pediatrics/standards ; Personal Protective Equipment/standards/supply & distribution ; Pneumonia, Viral/epidemiology/*prevention & control/virology ; Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical/organization & administration ; Voice Disorders/diagnosis/surgery/virology ; },
abstract = {BACKGROUND: The following position statement from the Union of the European Phoniatricians, updated on 25th May 2020 (superseding the previous statement issued on 21st April 2020), contains a series of recommendations for phoniatricians and ENT surgeons who provide and/or run voice, swallowing, speech and language, or paediatric audiology services.

OBJECTIVES: This material specifically aims to inform clinical practices in countries where clinics and operating theatres are reopening for elective work. It endeavours to present a current European view in relation to common procedures, many of which fall under the aegis of aerosol generating procedures.

CONCLUSION: As evidence continues to build, some of the recommended practices will undoubtedly evolve, but it is hoped that the updated position statement will offer clinicians precepts on safe clinical practice.},
}

Audiology/*methods/standards
Betacoronavirus/*isolation & purification
COVID-19
Child
Child, Preschool
Coronavirus Infections/epidemiology/*prevention & control/virology
Deglutition Disorders/diagnosis/surgery/virology
Europe/epidemiology
Humans
Mandatory Testing/standards
Otolaryngology/*methods/standards
Pandemics/*prevention & control
Pediatrics/standards
Personal Protective Equipment/standards/supply & distribution
Pneumonia, Viral/epidemiology/*prevention & control/virology
Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical/organization & administration
Voice Disorders/diagnosis/surgery/virology

@article {pmid32601022,
year = {2020},
author = {Parsonage, WA and Cullen, L and Brieger, D and Hillis, GS and Nasis, A and Dwyer, N and Wahi, S and Lo, S and Than, M and Kerr, A and Devlin, G and Chew, DK},
title = {CSANZ Position Statement on the Evaluation of Patients Presenting With Suspected Acute Coronary Syndromes During the COVID-19 Pandemic.},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e105-e110},
pmid = {32601022},
issn = {1444-2892},
mesh = {*Acute Coronary Syndrome/diagnosis/epidemiology/therapy ; Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiology/methods/organization & administration/trends ; *Communicable Disease Control/methods/organization & administration ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Humans ; Infection Control/*organization & administration ; New Zealand/epidemiology ; *Pandemics/prevention & control ; Patient Care Management/*methods ; *Pneumonia, Viral/epidemiology/prevention & control ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {A pandemic of Coronavirus-19 disease was declared by the World Health Organization on March 11, 2020. The pandemic is expected to place unprecedented demand on health service delivery. This position statement has been developed by the Cardiac Society of Australia and New Zealand to assist clinicians to continue to deliver rapid and safe evaluation of patients presenting with suspected acute cardiac syndrome at this time. The position statement complements, and should be read in conjunction with, the National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016: Section 2 'Assessment of Possible Cardiac Chest Pain'.},
}

*Acute Coronary Syndrome/diagnosis/epidemiology/therapy
Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiology/methods/organization & administration/trends
*Communicable Disease Control/methods/organization & administration
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Humans
Infection Control/*organization & administration
New Zealand/epidemiology
*Pandemics/prevention & control
Patient Care Management/*methods
*Pneumonia, Viral/epidemiology/prevention & control
SARS-CoV-2
Societies, Medical

@article {pmid32574446,
year = {2020},
author = {},
title = {UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.},
journal = {Undersea & hyperbaric medicine : journal of the Undersea and Hyperbaric Medical Society, Inc},
volume = {47},
number = {2},
pages = {297-298},
pmid = {32574446},
issn = {1066-2936},
mesh = {*Betacoronavirus ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/complications/*therapy ; Humans ; *Hyperbaric Oxygenation/adverse effects/methods ; Hypoxia/etiology/therapy ; Pandemics ; Pneumonia/etiology/therapy ; Pneumonia, Viral/complications/*therapy ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {There have been numerous recent inquiries regarding use of hyperbaric oxygen (HBO2) for patients with COVID-19. Questions have been raised pertinent to two possible mechanisms for HBO2 in this clinical context. The UHMS Hyperbaric Oxygen Therapy Committee, UHMS Executive Committee, with collaborative input from multiple senior UHMS members and researchers have drafted this position statement.},
}

*Betacoronavirus
COVID-19
Clinical Trials as Topic
Coronavirus Infections/complications/*therapy
Humans
*Hyperbaric Oxygenation/adverse effects/methods
Hypoxia/etiology/therapy
Pandemics
Pneumonia/etiology/therapy
Pneumonia, Viral/complications/*therapy
SARS-CoV-2
Societies, Medical

@article {pmid32548994,
year = {2020},
author = {Mureddu, GF and Ambrosetti, M and Venturini, E and La Rovere, MT and Mazza, A and Pedretti, R and Sarullo, F and Fattirolli, F and Faggiano, P and Giallauria, F and Vigorito, C and Angelino, E and Brazzo, S and Ruzzolini, M},
title = {Cardiac rehabilitation activities during the COVID-19 pandemic in Italy. Position Paper of the AICPR (Italian Association of Clinical Cardiology, Prevention and Rehabilitation).},
journal = {Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace},
volume = {90},
number = {2},
pages = {},
doi = {10.4081/monaldi.2020.1439},
pmid = {32548994},
issn = {2532-5264},
mesh = {Acute Coronary Syndrome/rehabilitation ; COVID-19 ; Cardiac Rehabilitation/psychology/*standards ; Cardiotonic Agents/adverse effects/therapeutic use ; Coronavirus Infections/*epidemiology ; Exercise ; Female ; Heart Failure/rehabilitation ; Humans ; Italy/epidemiology ; Male ; Nutrition Therapy ; Pandemics ; Pneumonia, Viral/*epidemiology ; Thromboembolism/rehabilitation ; },
abstract = {The COVID-19 outbreak is having a significant impact on both cardiac rehabilitation (CR) inpatient and outpatient healthcare organization. The variety of clinical and care scenarios we are observing in Italy depends on the region, the organization of local services and the hospital involved. Some hospital wards have been closed to make room to dedicated beds or to quarantine the exposed health personnel. In other cases, CR units have been converted or transformed into COVID-19 units. The present document aims at defining the state of the art of CR during COVID-19 pandemic, through the description of the clinical and management scenarios frequently observed during this period and the exploration of the future frontiers in the management of cardiac rehabilitation programs after the COVID-19 outbreak.},
}

Acute Coronary Syndrome/rehabilitation
COVID-19
Cardiac Rehabilitation/psychology/*standards
Cardiotonic Agents/adverse effects/therapeutic use
Coronavirus Infections/*epidemiology
Exercise
Female
Heart Failure/rehabilitation
Humans
Italy/epidemiology
Male
Nutrition Therapy
Pandemics
Pneumonia, Viral/*epidemiology
Thromboembolism/rehabilitation

@article {pmid32541561,
year = {2020},
author = {Zidan, A and Alabbad, S and Ali, T and Nizami, I and Haberal, M and Tokat, Y and Kamel, R and Said, H and Abdelaal, A and Elsharkawy, M and El Fouly, A and Sayed, H and Al-Mousawi, M and AlGhonaim, M and Broering, D},
title = {Position Statement of Transplant Activity in the Middle East in Era of COVID-19 Pandemic.},
journal = {Transplantation},
volume = {104},
number = {11},
pages = {2205-2207},
pmid = {32541561},
issn = {1534-6080},
mesh = {Betacoronavirus ; COVID-19 ; Coronavirus Infections/*epidemiology ; Delivery of Health Care/*standards ; Humans ; Middle East ; Organ Transplantation/statistics & numerical data/*trends ; Pandemics ; Pneumonia, Viral/*epidemiology ; SARS-CoV-2 ; },
}

Betacoronavirus
COVID-19
Coronavirus Infections/*epidemiology
Delivery of Health Care/*standards
Humans
Middle East
Organ Transplantation/statistics & numerical data/*trends
Pandemics
Pneumonia, Viral/*epidemiology
SARS-CoV-2

@article {pmid32537929,
year = {2020},
author = {Hamad, N and Gottlieb, D and Ritchie, D and Kennedy, G and Watson, AM and Greenwood, M and Doocey, R and Perera, T and Spencer, A and Wong, E and O'Brien, T and Shaw, P and Conyers, R and Cole, T and Milliken, S and Bardy, P and Larsen, S and Lai, H and Butler, A and Fraser, C and Bajel, A and Butler, J and Kerridge, I and Purtill, D},
title = {Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement.},
journal = {Internal medicine journal},
volume = {50},
number = {6},
pages = {774-775},
doi = {10.1111/imj.14867},
pmid = {32537929},
issn = {1445-5994},
mesh = {Australia ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques/*methods/statistics & numerical data ; Comorbidity ; *Consensus ; Coronavirus Infections/*diagnosis/physiopathology/therapy/virology ; Cryopreservation ; Hematopoietic Stem Cell Transplantation/*methods ; Humans ; Leukemia/physiopathology/*therapy ; New Zealand ; Pandemics ; Pneumonia, Viral/*diagnosis/physiopathology/therapy/virology ; Practice Guidelines as Topic ; Triage ; },
}

Australia
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques/*methods/statistics & numerical data
Comorbidity
*Consensus
Coronavirus Infections/*diagnosis/physiopathology/therapy/virology
Cryopreservation
Hematopoietic Stem Cell Transplantation/*methods
Humans
Leukemia/physiopathology/*therapy
New Zealand
Pandemics
Pneumonia, Viral/*diagnosis/physiopathology/therapy/virology
Practice Guidelines as Topic
Triage

@article {pmid32531110,
year = {2021},
author = {Pfaar, O and Klimek, L and Jutel, M and Akdis, CA and Bousquet, J and Breiteneder, H and Chinthrajah, S and Diamant, Z and Eiwegger, T and Fokkens, WJ and Fritsch, HW and Nadeau, KC and O'Hehir, RE and O'Mahony, L and Rief, W and Sampath, V and Schedlowski, M and Torres, MJ and Traidl-Hoffmann, C and Wang, Y and Zhang, L and Bonini, M and Brehler, R and Brough, HA and Chivato, T and Del Giacco, SR and Dramburg, S and Gawlik, R and Gelincik, A and Hoffmann-Sommergruber, K and Hox, V and Knol, EF and Lauerma, A and Matricardi, PM and Mortz, CG and Ollert, M and Palomares, O and Riggioni, C and Schwarze, J and Skypala, I and Untersmayr, E and Walusiak-Skorupa, J and Ansotegui, IJ and Bachert, C and Bedbrook, A and Bosnic-Anticevich, S and Brussino, L and Canonica, GW and Cardona, V and Carreiro-Martins, P and Cruz, AA and Czarlewski, W and Fonseca, JA and Gotua, M and Haahtela, T and Ivancevich, JC and Kuna, P and Kvedariene, V and Larenas-Linnemann, DE and Abdul Latiff, AH and Mäkelä, M and Morais-Almeida, M and Mullol, J and Naclerio, R and Ohta, K and Okamoto, Y and Onorato, GL and Papadopoulos, NG and Patella, V and Regateiro, FS and Samoliński, B and Suppli Ulrik, C and Toppila-Salmi, S and Valiulis, A and Ventura, MT and Yorgancioglu, A and Zuberbier, T and Agache, I},
title = {COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.},
journal = {Allergy},
volume = {76},
number = {3},
pages = {648-676},
pmid = {32531110},
issn = {1398-9995},
mesh = {Allergists ; COVID-19/*epidemiology/prevention & control ; Health Personnel ; Humans ; Hypersensitivity/diagnosis/*therapy ; Information Technology ; Patient Care Team ; *SARS-CoV-2 ; Triage ; },
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.

METHOD: The scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet.

RESULTS: Based on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the "Allergic Rhinitis and its Impact on Asthma (ARIA)" initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.

CONCLUSIONS: This international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic.},
}

Allergists
COVID-19/*epidemiology/prevention & control
Health Personnel
Humans
Hypersensitivity/diagnosis/*therapy
Information Technology
Patient Care Team
*SARS-CoV-2
Triage

@article {pmid32513287,
year = {2020},
author = {Campanile, FC and Podda, M and Arezzo, A and Botteri, E and Sartori, A and Guerrieri, M and Cassinotti, E and Muttillo, I and Pisano, M and Brachet Contul, R and D'Ambrosio, G and Cuccurullo, D and Bergamini, C and Allaix, ME and Caracino, V and Petz, WL and Milone, M and Silecchia, G and Anania, G and Agrusa, A and Di Saverio, S and Casarano, S and Cicala, C and Narilli, P and Federici, S and Carlini, M and Paganini, A and Bianchi, PP and Salaj, A and Mazzari, A and Meniconi, RL and Puzziello, A and Terrosu, G and De Simone, B and Coccolini, F and Catena, F and Agresta, F},
title = {Acute cholecystitis during COVID-19 pandemic: a multisocietary position statement.},
journal = {World journal of emergency surgery : WJES},
volume = {15},
number = {1},
pages = {38},
pmid = {32513287},
issn = {1749-7922},
mesh = {Betacoronavirus ; COVID-19 ; Cholecystectomy/methods/*standards ; Cholecystitis, Acute/*surgery/virology ; Coronavirus Infections/*complications/virology ; Humans ; Infection Control/*standards ; Pandemics ; Pneumonia, Viral/*complications/virology ; *Practice Guidelines as Topic ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {Following the spread of the infection from the new SARS-CoV2 coronavirus in March 2020, several surgical societies have released their recommendations to manage the implications of the COVID-19 pandemic for the daily clinical practice. The recommendations on emergency surgery have fueled a debate among surgeons on an international level.We maintain that laparoscopic cholecystectomy remains the treatment of choice for acute cholecystitis, even in the COVID-19 era. Moreover, since laparoscopic cholecystectomy is not more likely to spread the COVID-19 infection than open cholecystectomy, it must be organized in such a way as to be carried out safely even in the present situation, to guarantee the patient with the best outcomes that minimally invasive surgery has shown to have.},
}

Betacoronavirus
COVID-19
Cholecystectomy/methods/*standards
Cholecystitis, Acute/*surgery/virology
Coronavirus Infections/*complications/virology
Humans
Infection Control/*standards
Pandemics
Pneumonia, Viral/*complications/virology
*Practice Guidelines as Topic
SARS-CoV-2
Societies, Medical

@article {pmid32501145,
year = {2020},
author = {Linnemann, B and Bauersachs, R and Grebe, M and Klamroth, R and Müller, O and Schellong, S and Lichtenberg, M},
title = {Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).},
journal = {VASA. Zeitschrift fur Gefasskrankheiten},
volume = {49},
number = {4},
pages = {259-263},
doi = {10.1024/0301-1526/a000885},
pmid = {32501145},
issn = {0301-1526},
mesh = {Anticoagulants/*administration & dosage ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/*complications ; Humans ; Pandemics ; Pneumonia, Viral/*complications ; SARS-CoV-2 ; *Venous Thromboembolism ; },
abstract = {As observed in other infections with a systemic inflammatory response, severe COVID-19 is associated with hypercoagulability and a prothrombotic state. Currently, there is growing evidence that pulmonary embolism and thrombosis contribute to adverse outcomes and increased mortality in critically ill patients with COVID-19. The optimal thromboprophylactic regimen for patients with COVID-19 is not known. Whereas pharmacologic thromboprophylaxis is generally recommended for all hospitalized COVID-19 patients, adequate dosing of anticoagulants remains a controversial issue. Therefore, we summarize current evidence from the available literature and, on behalf of the German Society of Angiology (DGA), we aim to provide advice to establish an improved and more uniform strategy for thromboprophylaxis in patients with COVID-19.},
}

Anticoagulants/*administration & dosage
Betacoronavirus
COVID-19
Coronavirus Infections/*complications
Humans
Pandemics
Pneumonia, Viral/*complications
SARS-CoV-2
*Venous Thromboembolism

@article {pmid32500283,
year = {2020},
author = {Stolbach, AI and Mazer-Amirshahi, M and Marino, R and Nelson, LS and Sugarman, J},
title = {ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {3},
pages = {342-345},
pmid = {32500283},
issn = {1937-6995},
mesh = {Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/*drug therapy ; Emergency Medical Services/*standards ; Humans ; Off-Label Use/*standards/*statistics & numerical data ; Pandemics ; Pneumonia, Viral/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; United States ; United States Food and Drug Administration ; },
}

Betacoronavirus/drug effects
COVID-19
Coronavirus Infections/*drug therapy
Emergency Medical Services/*standards
Humans
Off-Label Use/*standards/*statistics & numerical data
Pandemics
Pneumonia, Viral/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2
United States
United States Food and Drug Administration

@article {pmid32489251,
year = {2020},
author = {Ahmed, S and Barbera, L and Bartlett, SJ and Bebb, DG and Brundage, M and Bryan, S and Cheung, WY and Coburn, N and Crump, T and Cuthbertson, L and Howell, D and Klassen, AF and Leduc, S and Li, M and Mayo, NE and McKinnon, G and Olson, R and Pink, J and Robinson, JW and Santana, MJ and Sawatzky, R and Moxam, RS and Sinclair, S and Servidio-Italiano, F and Temple, W},
title = {A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.},
journal = {Current oncology (Toronto, Ont.)},
volume = {27},
number = {2},
pages = {90-99},
pmid = {32489251},
issn = {1718-7729},
mesh = {Canada ; Delivery of Health Care/methods/standards/*statistics & numerical data ; Humans ; Medical Oncology/methods/standards/*statistics & numerical data ; Neoplasms/diagnosis/*therapy ; *Patient Reported Outcome Measures ; Patient-Centered Care/methods/standards/*statistics & numerical data ; Quality of Life ; },
abstract = {BACKGROUND: Patient-reported outcomes (pros) are essential to capture the patient's perspective and to influence care. Although pros and pro measures are known to have many important benefits, they are not consistently being used and there is there no Canadian pros oversight. The Position Statement presented here is the first step toward supporting the implementation of pros in the Canadian health care setting.

METHODS: The Canadian pros National Steering Committee drafted position statements, which were submitted for stakeholder feedback before, during, and after the first National Canadian Patient Reported Outcomes (canpros) scientific conference, 14-15 November 2019 in Calgary, Alberta. In addition to the stakeholder feedback cycle, a patient advocate group submitted a section to capture the patient voice.

RESULTS: The canpros Position Statement is an outcome of the 2019 canpros scientific conference, with an oncology focus. The Position Statement is categorized into 6 sections covering 4 theme areas: Patient and Families, Health Policy, Clinical Implementation, and Research. The patient voice perfectly mirrors the recommendations that the experts reached by consensus and provides an overriding impetus for the use of pros in health care.

CONCLUSIONS: Although our vision of pros transforming the health care system to be more patient-centred is still aspirational, the Position Statement presented here takes a first step toward providing recommendations in key areas to align Canadian efforts. The Position Statement is directed toward a health policy audience; future iterations will target other audiences, including researchers, clinicians, and patients. Our intent is that future versions will broaden the focus to include chronic diseases beyond cancer.},
}

Canada
Delivery of Health Care/methods/standards/*statistics & numerical data
Humans
Medical Oncology/methods/standards/*statistics & numerical data
Neoplasms/diagnosis/*therapy
*Patient Reported Outcome Measures
Patient-Centered Care/methods/standards/*statistics & numerical data
Quality of Life

@article {pmid32487434,
year = {2020},
author = {Lal, S and Van Gossum, A and Joly, F and Bozzetti, F and Cuerda, C and Lamprecht, G and Mundi, MS and Staun, M and Szczepanek, K and Wanten, G and Wheatley, C and Pironi, L and , },
title = {Considerations for the management of home parenteral nutrition during the SARS-CoV-2 pandemic: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN.},
journal = {Clinical nutrition (Edinburgh, Scotland)},
volume = {39},
number = {7},
pages = {1988-1991},
pmid = {32487434},
issn = {1532-1983},
mesh = {Betacoronavirus ; COVID-19 ; Chronic Disease ; *Coronavirus Infections/complications/therapy ; Hospitalization ; Humans ; *Intestinal Diseases/complications/therapy ; *Pandemics ; *Parenteral Nutrition, Home ; *Pneumonia, Viral/complications/therapy ; Practice Guidelines as Topic ; SARS-CoV-2 ; },
abstract = {The management of patients with chronic intestinal failure requiring home parenteral nutrition has been and will continue to be impaired during the SARS-CoV-2 pandemic. Multidisciplinary intestinal failure teams may have to adapt their clinical approaches to home care, outpatient care as well as hospital admission and discharge in order to keep this vulnerable group of patients as safe and well as possible during the unprecedented challenges that countries are facing during the pandemic. Equally, it is important that expert advice from intestinal failure teams is available when home parenteral nutrition (HPN)-dependent patients require admission with SARS-CoV-2 infection. The Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of the European Society for Clinical Nutrition and Metabolism (ESPEN) has developed a position paper to outline areas for intestinal failure teams to consider when managing patients with chronic intestinal failure during the SARS-CoV-2 pandemic.},
}

Betacoronavirus
COVID-19
Chronic Disease
*Coronavirus Infections/complications/therapy
Hospitalization
Humans
*Intestinal Diseases/complications/therapy
*Pandemics
*Parenteral Nutrition, Home
*Pneumonia, Viral/complications/therapy
Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32473781,
year = {2020},
author = {Nicholls, SJ and Nelson, M and Astley, C and Briffa, T and Brown, A and Clark, R and Colquhoun, D and Gallagher, R and Hare, DL and Inglis, S and Jelinek, M and O'Neil, A and Tirimacco, R and Vale, M and Redfern, J},
title = {Optimising Secondary Prevention and Cardiac Rehabilitation for Atherosclerotic Cardiovascular Disease During the COVID-19 Pandemic: A Position Statement From the Cardiac Society of Australia and New Zealand (CSANZ).},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e99-e104},
pmid = {32473781},
issn = {1444-2892},
mesh = {Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiac Rehabilitation/methods/trends ; *Cardiology/methods/organization & administration/trends ; *Cardiovascular Diseases/complications/epidemiology/prevention & control ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Delivery of Health Care/organization & administration ; Humans ; Infection Control/*organization & administration ; New Zealand/epidemiology ; *Pandemics/prevention & control ; *Pneumonia, Viral/epidemiology/prevention & control ; SARS-CoV-2 ; *Secondary Prevention/methods/organization & administration ; Societies, Medical ; },
abstract = {BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has introduced a major disruption to the delivery of routine health care across the world. This provides challenges for the use of secondary prevention measures in patients with established atherosclerotic cardiovascular disease (CVD). The aim of this Position Statement is to review the implications for effective delivery of secondary prevention strategies during the COVID-19 pandemic.

CHALLENGES: The COVID-19 pandemic has introduced limitations for many patients to access standard health services such as visits to health care professionals, medications, imaging and blood tests as well as attendance at cardiac rehabilitation. In addition, the pandemic is having an impact on lifestyle habits and mental health. Taken together, this has the potential to adversely impact the ability of practitioners and patients to adhere to treatment guidelines for the prevention of recurrent cardiovascular events.

RECOMMENDATIONS: Every effort should be made to deliver safe, ongoing access to health care professionals and the use of evidenced based therapies in individuals with CVD. An increase in use of a range of electronic health platforms has the potential to transform secondary prevention. Integrating research programs that evaluate the utility of these approaches may provide important insights into how to develop more optimal approaches to secondary prevention beyond the pandemic.},
}

Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiac Rehabilitation/methods/trends
*Cardiology/methods/organization & administration/trends
*Cardiovascular Diseases/complications/epidemiology/prevention & control
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Delivery of Health Care/organization & administration
Humans
Infection Control/*organization & administration
New Zealand/epidemiology
*Pandemics/prevention & control
*Pneumonia, Viral/epidemiology/prevention & control
SARS-CoV-2
*Secondary Prevention/methods/organization & administration
Societies, Medical

@article {pmid32467031,
year = {2020},
author = {Wahi, S and Thomas, L and Stanton, T and Taylor, A and Mahadevan, D and Evans, G and Playford, D and To, A and Davis, M and Anderson, B and Buckley, B},
title = {CSANZ Imaging Council Position Statement on Echocardiography Services During the COVID-19 Pandemic.},
journal = {Heart, lung & circulation},
volume = {29},
number = {6},
pages = {e78-e83},
pmid = {32467031},
issn = {1444-2892},
mesh = {Australia/epidemiology ; *Betacoronavirus ; COVID-19 ; Cardiology ; *Coronavirus Infections/diagnostic imaging/epidemiology ; Delivery of Health Care/*standards ; Echocardiography/*standards ; Humans ; New Zealand/epidemiology ; *Pandemics ; *Pneumonia, Viral/diagnostic imaging/epidemiology ; Positron-Emission Tomography/*standards ; Risk Assessment ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {This Cardiac Society of Australia and New Zealand (CSANZ) Imaging Council Position Statement aims to guide local, regional and national clinical practice, and facilitate resource and echocardiographic service planning appropriately during the current COVID-19 global pandemic. General considerations include workforce arrangements and contingency plans, patient risk assessment for COVID-19 and level of care (personal protective equipment) for staff. Both outpatient and inpatient settings are addressed, including specific considerations in the in-patient setting including scanning protocols, screening modalities and indications for echocardiograms in the context of COVID-19 infection.},
}

Australia/epidemiology
*Betacoronavirus
COVID-19
Cardiology
*Coronavirus Infections/diagnostic imaging/epidemiology
Delivery of Health Care/*standards
Echocardiography/*standards
Humans
New Zealand/epidemiology
*Pandemics
*Pneumonia, Viral/diagnostic imaging/epidemiology
Positron-Emission Tomography/*standards
Risk Assessment
SARS-CoV-2
Societies, Medical

@article {pmid32451232,
year = {2020},
author = {Kumar, S and Haqqani, H and Wynn, G and Pathak, RK and Lipton, J and Mahajan, R and Sanders, P and Healey, S and Wilsmore, B and Mariani, JA and Thomas, SP and Weerasooriya, R and McGavigan, A and Gould, PA and Weatherley, P and Saad, N and Cowan, M and Turnbull, S and Trivic, I and Wong, M and Tonchev, I and Morton, JB and Skinner, JR and Pflaumer, A and McGuire, M and Kistler, P and Kalman, JM and , },
title = {Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document.},
journal = {Heart, lung & circulation},
volume = {29},
number = {6},
pages = {e57-e68},
pmid = {32451232},
issn = {1444-2892},
mesh = {Australia/epidemiology ; *Betacoronavirus ; COVID-19 ; *Coronavirus Infections/epidemiology/physiopathology/therapy ; *Defibrillators, Implantable ; *Electrophysiologic Techniques, Cardiac ; Humans ; *Pandemics ; *Pneumonia, Viral/epidemiology/physiopathology/therapy ; SARS-CoV-2 ; },
abstract = {The COVID-19 pandemic poses a significant stress on health resources in Australia. The Heart Rhythm Council of the Cardiac Society of Australia and New Zealand aims to provide a framework for efficient resource utilisation balanced with competing risks when appropriately treating patients with cardiac arrhythmias. This document provides practical recommendations for the electrophysiology (EP) and cardiac implantable electronic devices (CIED) services in Australia. The document will be updated regularly as new evidence and knowledge is gained with time.},
}

Australia/epidemiology
*Betacoronavirus
COVID-19
*Coronavirus Infections/epidemiology/physiopathology/therapy
*Defibrillators, Implantable
*Electrophysiologic Techniques, Cardiac
Humans
*Pandemics
*Pneumonia, Viral/epidemiology/physiopathology/therapy
SARS-CoV-2

@article {pmid32425181,
year = {2020},
author = {Bonalumi, G and Di Mauro, M and Garatti, A and Barili, F and Parolari, A and Gerosa, G},
title = {[COVID-19 outbreak and Cardiac Surgery: position paper from the COVID-SICCH Task Force of the Italian Society for Cardiac Surgery].},
journal = {Giornale italiano di cardiologia (2006)},
volume = {21},
number = {6},
pages = {396-400},
doi = {10.1714/3359.33320},
pmid = {32425181},
issn = {1972-6481},
mesh = {COVID-19 ; Cardiovascular Surgical Procedures/methods/*standards ; Coronavirus Infections/*complications ; Humans ; Italy ; Pandemics ; Pneumonia, Viral/*complications ; *Practice Guidelines as Topic ; Risk Assessment ; Societies, Medical ; },
}

COVID-19
Cardiovascular Surgical Procedures/methods/*standards
Coronavirus Infections/*complications
Humans
Italy
Pandemics
Pneumonia, Viral/*complications
*Practice Guidelines as Topic
Risk Assessment
Societies, Medical

@article {pmid32418875,
year = {2020},
author = {Lal, S and Hayward, CS and De Pasquale, C and Kaye, D and Javorsky, G and Bergin, P and Atherton, JJ and Ilton, MK and Weintraub, RG and Nair, P and Rudas, M and Dembo, L and Doughty, RN and Kumarasinghe, G and Juergens, C and Bannon, PG and Bart, NK and Chow, CK and Lattimore, JD and Kritharides, L and Totaro, R and Macdonald, PS},
title = {COVID-19 and Acute Heart Failure: Screening the Critically Ill - A Position Statement of the Cardiac Society of Australia and New Zealand (CSANZ).},
journal = {Heart, lung & circulation},
volume = {29},
number = {7},
pages = {e94-e98},
pmid = {32418875},
issn = {1444-2892},
mesh = {Australia/epidemiology ; Betacoronavirus ; COVID-19 ; *Cardiology/methods/organization & administration/trends ; Consensus ; *Coronavirus Infections/epidemiology/prevention & control ; Critical Illness/therapy ; *Heart Failure/diagnosis/etiology/therapy ; Humans ; *Infection Control/methods/organization & administration ; *Myocarditis/complications/virology ; New Zealand/epidemiology ; *Pandemics/prevention & control ; Patient Care Management/*methods ; *Pneumonia, Viral/epidemiology/prevention & control ; Risk Adjustment/methods ; SARS-CoV-2 ; Societies, Medical ; },
abstract = {Up to one-third of COVID-19 patients admitted to intensive care develop an acute cardiomyopathy, which may represent myocarditis or stress cardiomyopathy. Further, while mortality in older patients with COVID-19 appears related to multi-organ failure complicating acute respiratory distress syndrome (ARDS), the cause of death in younger patients may be related to acute heart failure. Cardiac involvement needs to be considered early on in critically ill COVID-19 patients, and even after the acute respiratory phase is passing. This Statement presents a screening algorithm to better identify COVID-19 patients at risk for severe heart failure and circulatory collapse, while balancing the need to protect health care workers and preserve personal protective equipment (PPE). The significance of serum troponin levels and the role of telemetry and targeted transthoracic echocardiography (TTE) in patient investigation and management are addressed, as are fundamental considerations in the management of acute heart failure in COVID-19 patients.},
}

Australia/epidemiology
Betacoronavirus
COVID-19
*Cardiology/methods/organization & administration/trends
Consensus
*Coronavirus Infections/epidemiology/prevention & control
Critical Illness/therapy
*Heart Failure/diagnosis/etiology/therapy
Humans
*Infection Control/methods/organization & administration
*Myocarditis/complications/virology
New Zealand/epidemiology
*Pandemics/prevention & control
Patient Care Management/*methods
*Pneumonia, Viral/epidemiology/prevention & control
Risk Adjustment/methods
SARS-CoV-2
Societies, Medical

@article {pmid32418120,
year = {2020},
author = {Mazer-Amirshahi, M and Fox, ER and Farmer, BM and Stolbach, AI},
title = {ACMT Position Statement: Medication Shortages During Coronavirus Disease Pandemic.},
journal = {Journal of medical toxicology : official journal of the American College of Medical Toxicology},
volume = {16},
number = {3},
pages = {346-348},
pmid = {32418120},
issn = {1937-6995},
mesh = {Antiviral Agents/*supply & distribution/*therapeutic use ; Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/*drug therapy ; Humans ; Medication Systems, Hospital/*standards/*statistics & numerical data ; Pandemics ; Pneumonia, Viral/*drug therapy ; *Practice Guidelines as Topic ; SARS-CoV-2 ; },
}

Antiviral Agents/*supply & distribution/*therapeutic use
Betacoronavirus/drug effects
COVID-19
Coronavirus Infections/*drug therapy
Humans
Medication Systems, Hospital/*standards/*statistics & numerical data
Pandemics
Pneumonia, Viral/*drug therapy
*Practice Guidelines as Topic
SARS-CoV-2

@article {pmid32414880,
year = {2020},
author = {Rubin, MA and Bonnie, RJ and Epstein, L and Hemphill, C and Kirschen, M and Lewis, A and Suarez, JI and , },
title = {AAN position statement: The COVID-19 pandemic and the ethical duties of the neurologist.},
journal = {Neurology},
volume = {95},
number = {4},
pages = {167-172},
doi = {10.1212/WNL.0000000000009744},
pmid = {32414880},
issn = {1526-632X},
mesh = {COVID-19 ; Coronavirus Infections/complications/*therapy ; Health Resources ; Humans ; Nervous System Diseases/complications ; Neurologists/*ethics ; Neurology/education/*ethics ; Pandemics/*ethics ; Pneumonia, Viral/complications/*therapy ; Referral and Consultation ; Societies, Medical ; Telemedicine ; },
abstract = {Patients, clinicians, and hospitals have undergone monumental changes during the coronavirus disease 2019 (COVID-19) pandemic. This crisis has forced us to consider the obligations that we neurologists have to our individual patients as well as the greater community. By returning to our fundamental understanding of these duties, we can ensure that we are providing the most ethically appropriate contingency and crisis care possible. We recommend specific adaptations to both the inpatient and outpatient settings, as well as changes to medical and trainee education. Furthermore, we explore the daunting but potentially necessary implementation of scare resource allocation protocols. As the pandemic evolves, we will need to adapt continuously to these rapidly changing circumstances and consider both national and regional standards and variation.},
}

COVID-19
Coronavirus Infections/complications/*therapy
Health Resources
Humans
Nervous System Diseases/complications
Neurologists/*ethics
Neurology/education/*ethics
Pandemics/*ethics
Pneumonia, Viral/complications/*therapy
Referral and Consultation
Societies, Medical
Telemedicine